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1 Summary
Inbred mouse strains are powerful tools to study the complexity of the immune system. How-
ever, especially in immunology, the choice of the respective mouse strain might also greatly
alter the outcome of a study, as factors such as differential gene mutations, polymorphisms
and regulation strongly influence the results.
In this study we analyzed the constitutive CD40-triggering of dendritic cells (DCs), its in-
fluence on DC maturation, DC homeostasis and the effects on peripheral tolerance induction.
For this purpose we used the DC-LMP1/CD40 mice expressing a constitutive LMP1/CD40
transgene in all CD11c expressing cells, to provide the expressing cell with a constant CD40
stimulation. CD40 stimulation has previously been connected with the maturation of DCs
and in our mouse model, when combined with a normal intestinal flora of commensal bacteria,
resulted in a fatal B- and T-cell dependent colitis. Surprisingly this held true only for trans-
genic animals on C57BL/6 genetic background, while animals on F1 (C57BL/6 x BALB/c)
and BALB/c genetic backgrounds remained healthy.
Here we analyzed the phenotypical differences between DC-LMP1/CD40 animals of differ-
ent genetic backgrounds. We demonstrated that transgenic animals on a C57BL/6 genetic
background had the strongest reduction of tolerogenic CD103+ DCs causing the absence of
induced regulatory T cells (iTregs) and increase of Th1/Th17 effector T cells, which were
responsible for colitis. In contrast, DC-LMP1/CD40 mice on BALB/c and F1 backgrounds
showed higher frequencies of tolerogenic CD103+ DCs, more iTregs and less or no effector T
cells.
We also showed that high levels of IL-1𝛽, which were present only in C57BL/6 DC-LMP1/-
CD40 animals, formed a cytokine milieu, which was favorable for the development of the
pathogenic Th1/Th17 T cells. In agreement with this, blocking of IL-1𝛽 prevented disease
development by reducing IL-17−IFN-𝛾+ T cells.
Our data provides evidence that the genetic background contributes to disease development
by differentially affecting key immune cell populations such as DCs and iTregs.
2 Zusammenfassung
Durch Inzucht erzeugte Mauslinien sind leistungsstarke Werkzeuge zur Erforschung des Im-
munsystems. Allerdings bestimmt die Auswahl des genetischen Hintergrundes der verwen-
deten Mauslinien auch das zu erzielende Ergebnis. Da unterschiedliche Mauslinien unter-
schiedliche Genmutationen und Polymorphismen tragen, führen identische Experimente in
unterschiedlichen Mauslinien unter Umständen zu unterschiedlichen Ergebnissen. In der vor-
liegenden Studie untersuchen wir den Einfluss des CD40 Signals auf dendritische Zellen (DC),
ihre Reifung, Homeostase und periphere Toleranzinduktion. Zu diesem Zweck wurde das
DC-LMP1/CD40 Mausmodell verwendet, welches ein konstitutives LMP1/CD40 Transgen
in allen CD11c-positiven Zellen exprimiert, welches wiederum die exprimierende Zelle mit
kontinuierlicher CD40 Stimulierung versorgt. CD40 Stimulation wurde zuvor bereits mit der
Reifung von DC in unserem Mausmodell in Verbindung gebracht. In Kombination mit einer
normalen Darmflora führte CD40 Stimulation zu einer tödlichen, B- und T-Zell abhängigen
Kolitis. Überraschenderweise war dies nur der Fall nur bei transgenen Tieren des genetis-
chem C57BL/6-Hintergrundes, während Tiere im BALB/c- oder F1 (C57BL/6 x BALB/c)
Hintergrund gesund blieben.
Wir analysieren die phänotypischen Unterschiede von DC-LMP1/CD40 Tieren mit unter-
schiedlichem genetischen Hintergrund und zeigen, dass transgene Tiere im C57BL/6 Hinter-
grund die geringste Anzahl an toleranten CD103+ DCs haben. Dies führt zu einer starken
Reduktion von induzierten regulatorischen T Zellen (iTregs), einer Erhöhung von Th1/Th17
Effektor T-Zellen, welche die Krankheit verursachten. Die Anzahl an toleranten CD103+ DCs
war in transgenen Tieren mit anderem genetischen Hintergrund weniger reduziert, was sich
wiederum in einem Anstieg an iTregs wiederspiegelte, welche in der Lage waren die Entzün-
dung zu kontrollieren. Außerdem zeigten wir, dass hohe IL-1𝛽 Level, welche nur in C57BL/6
DC-LMP1/CD40 Tieren vorzufinden waren, ein Zytokinmilieu erzeugten, welches sich positiv
auf die Entwicklung von pathogenen Th1/Th17 T Zellen auswirkte. In Übereinstimmung mit
diesen Ergebnissen konnten die Blockierung von IL-1𝛽 die Krankheitsentwicklung verhindern
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und die Anzahl von IL-17−IFN-𝛾+ T Zellen verringern. Dies veranschaulicht die Bedeutung
von IL-1𝛽 für die Differenzierung von Th17 T Zellen und legt eine mögliche Verwendung von
anti-IL-1𝛽 für die Behandlung von Patienten mit chronisch-entzündlichen Darmerkrankun-
gen (IBDs) nahe. Unsere Ergebnise zeigen, dass der genetische Hintergrund zur Krankheit-
entwicklung beiträgt indem wichtige Immunzellen wie DCs und iTregs unterschiedlich stark
beeinflusst werden.
3 Introduction
3.1 The immune system
The immune system is a complex integrated network of organs, tissues, cells and their prod-
ucts that work together to defend an organism from invasion and infection. Its main feature is
to differentiate between self and non-self antigens. Self antigens have to be tolerated. While
pathogenic bacteria, fungi or protozoa expressing non-self antigens have to be neutralized
or destroyed, antigens on commensal bacteria should be tolerated. Disorders in the immune
system can result in serious autoimmune diseases when the immune system targets the body’s
own healthy tissues, or in allergies when the immune system performs an exaggerated response
against a harmless material like for example grass pollen, food particles or pet dander. The
immune system is built from layered defenses of increasing specificity. There are two arms of
the immune response: the innate and the adaptive immune system, which complement each
other. The innate immune system is activated when conserved small molecular motifs asso-
ciated with groups of pathogens, so-called pathogen-associated molecular patterns (PAMPs),
are detected with toll-like receptors (TLRs) or others pattern recognition receptors (PRRs)
of the innate immune system. This is the so called first line of defense and offers immedi-
ate protection, but protection is not specific and it does not lead to immunological memory.
The innate immune system consist of mechanical barriers (epithelial surfaces, tight junc-
tions, mucosa), cells that release different inflammatory mediators (natural killer (NK) cells,
macrophages, mast cells, innate lymphocytes), cells with phagocytic activity (neutrophils,
monocytes, macrophages) and different proteins (proteins of complement system, interleukins,
defensins). The innate immune system is fast and broadly effective, but since it is not specific
it can only prevent entry and spreading of pathogens to a certain degree. More resistant
pathogens which overcome the first line of defense have to face the much more sophisticated,
highly specific, adaptive immune system, which is capable of destroying pathogens and neu-
tralizing the toxic substances produced by them. For induction of adaptive immune response
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in inactive or resting lymphocytes, special antigen presenting cells (APCs) are needed. Their
role is bridging the innate and adaptive immune systems, due to their ability to detect invad-
ing pathogens or altered body cells, process them and present their antigens on cell surfaces
in the context of major histocompatibility complex (MHC) molecules in combination with
necessary accessory co-stimulatory molecules. The so formed message is an activation signal
for T cells, while B cells have to recognize the native unprocessed antigen. B cells represents
the humoral response, due to their ability to make antibodies, which are secreted in extracel-
lular fluids where they bind and neutralize bacteria and toxins. The cellular response consist
of cytotoxic T cells, which recognize and kill infected or otherwise damaged cells, and from T
helper cells, which secrete cytokines that stimulate other cells and determine which immune
response strategy the body will use against a certain pathogen.
Each B or T cell bears many replicas of a receptor with a unique specificity made in a
process of V(D)J recombination, a process of antigen receptor rearrangement that enables
the production of a large repertoire of receptors from a limited amount of gene segments,
which can collectively recognize many different antigens. The price for the high antigen
specificity of the adoptive immune system is a low frequency of precursor cells resulting in
a long lag phase from selection of suitable cell clones with a specific antigen receptor and
the expansion of these clones to the point where they are able to fight infections. Due to
the random assembling of antigen receptors there exists a potential danger for self-reactivity,
meaning that lymphocytes bearing receptors for self molecules must be deleted or changed
in the early stage of maturation. This process is called immunological tolerance and will be
discussed later on. The final big advantage and main hallmark of the adoptive immune system
is immunological memory, which enables the system to remember previously encountered
pathogens by their antigens and if they are encountered again the antigen specific response
will be rapid and powerful.
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3.2 Immune tolerance
Antigen receptor rearrangement is a process of somatic recombination in immature lympho-
cytes which results in a large repertoire of antigen receptors with a potential to fight many
different pathogens. With random generation of antigen receptors many useful specificities
are generated, but so are many useless and potentially self reactive receptors, which have to
be deleted or rearranged.
B cells are continuously produced in bone marrow from hematopoietic precursor cells.
Before a newly formed B cell leaves the bone marrow and migrates to the spleen in order
to finalize its early development, it is tested for potential autoreactivity [1]. However, B cell
development will not be discussed in details, since this is not the focus of this thesis.
The thymus is the primary site of T cell lymphopoiesis from incoming bone-marrow-derived
progenitors [2]. Since T helper cells are able to activate B cells and cytotoxic T cells can attract
self tissue, potentially self reactive T cells represent big danger and have to be deleted, or
their receptors have to be edited in the process of tolerance induction [3].
3.2.1 Central T cell tolerance
The thymus is the primary lymphoid organ where central tolerance takes place. Once a T
cell receptor is formed and expressed on the cell surface large numbers of CD4+CD8+ double-
positive thymocytes enter a checking point where T-cell receptor (TCR) affinity for self MHC
determines the future fate of developing T cells [4]. If the TCR of a thymocyte does not bind to
self MHC, then the thymocyte will undergo the default death pathway, since this recognition
is a basic requirement for mature T cell functions [5]. Cells with a low TCR-MHC affinity
become CD4+ or CD8+ single positive T cells in a process called positive selection. As cells
with a high TCR-MHC affinity are potentially dangerous, they will be eliminated in a process
called clonal deletion, or are diverted clonally to become regulatory T cells (Tregs) and in rare
cases the specificity of their receptors might be changed in a process called receptor editing
[3]. Newly formed thymocytes then enter a process of negative selection where medullary
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thymic epithelial cells (mTECs), the APCs in thymus, facilitate tolerance induction against
self antigens. An expression of the diverse range of tissue specific self antigens in mTECs is
controlled by a transcriptional regulator encoded by the autoimmune regulatory (AIRE) gene
in order to remove auto-reactive T cells upon their encounter and recognition of self antigens
[6, 7].
3.2.2 Peripheral T cell tolerance
Central T cell tolerance is not able to eliminate self reactive lymphocytes, which are specific
for antigens not presented by mTECs, therefore there is a need for second mechanism. Pe-
ripheral tolerance controls T cells specific for developmental antigens and antigens displayed
during chronic infection as well as T cells specific for non-self non-dangerous antigens like
food antigens or commensal bacteria, which have to be tolerated and should not evoke an
aggressive immune response [3]. The main APCs in the periphery are DCs, which are strate-
gically positioned at body barriers like skin and mucosal surfaces, or are circulating in the
blood stream from where they can be rapidly recruited to sites of challenge in response to
chemotactic signals [8]. After having sampled the antigens they migrate through lymphatic
vessels in T cell zones in order to present processed antigens to naïve T cells [9]. DCs are mi-
grating to T cell zones in inflammatory and in steady state conditions, but due to the precise
regulation of their maturation status, which will be discussed further on, induce immunity
only against dangerous antigens whilst tolerating other antigens.
For full activation of a naïve T cell three signals are needed: signal one is mediated through
TCR after it binds a peptid presented in context of an MHC molecule, signal two comes from
co-stimulatory molecules on DCs, like for example CD80 and CD86, which bind to CD28 on
T cells. And the last signal, signal three, is a polarizing signal mediated by different soluble
or membrane bounded factors [10]. DCs provide signals two and three only if they have
previously detected PAMPs through receptors of the innate immune system. According to
that mature DCs induce immunity, because they have encountered a pathogen and conse-
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quently up-regulated MHC and co-stimulatory molecules on their surface. While immature
DCs provide only signal one to a naïve T cell and therefore induce tolerance [11, 12]. An
antigen, presented in low amounts [13] or presented by steady state DC therefore does not
induce clonal expansion of T cell with specific TCR for it. T cells which received only signal
one go into apoptosis [14], anergy [15] or they become Treg cells [16].
3.2.2.1 Tregs
Tregs are CD4+CD25+forkhead box protein P3 (FoxP3)+ primary mediators of peripheral
immune tolerance. FoxP3 is a key transcription factor in Treg cells and it is required for their
development and function [17, 18]. Consequently mutations resulting in a loss of function
lead to serious autoimmune diseases in humans and mice [19, 20, 21]. Tregs can suppress T
cell activation with the production of inhibitory cytokines, with the secretion of granzymes,
which cause cytolysis, or with the modulation of DCs maturation status [22].
Tregs consist of two developmentally different groups of cells. The first group are natural
regulatory T cells (nTregs), which develop in the thymus during the process of central T
cell tolerance, as a result of recognition of self antigens, and can be identified by expression
of Helios [23] or Neuropilin-1 [24]. The second group consists of iTregs, which develop in
the periphery from mature CD4+ T cells in the conditions where antigen exposure is not
optimal or T cells do not receive co-stimulatory signals from DCs [25]. The iTreg cells are
most prominently found in the intestinal organs, but are rare in other tissues. iTreg cells
express a key transcription factor nuclear hormone receptor ROR𝛾t and are dependent on
microbiota exposure, since they are profoundly reduced in germfree or antibiotic treated mice
(in contrast Helios positive Tregs are unaffected) [26].
In the gastrointestinal tract the immune system comes in close contact with a complex pop-
ulation of commensal bacteria and food antigens, which are all recognized by innate receptors
on DCs, but do not trigger effector T cells and rather induce peripheral iTreg cells. TCRs of
iTregs cells are of different specificity than those from nTregs, since they are shaped by local
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microflora [27]. The relative contribution of each of the two above described developmental
pathways to intestinal Treg population is still not completely understood and the system gets
even more complex since there is one more major subset of intestinal Tregs cells, which in
addition to Helios also expresses Gata3 and is negative for ROR𝛾t [26]. These Tregs are less
well described, but it is known that they respond to IL-33, which is an endogenous danger sig-
nal produced by epithelial cells [28]. Their intrinsic expression of transcription factor Gata3
was shown to be essential in inflammatory settings, where it controls the FoxP3 expression
and promotes the accumulation of Tregs in inflamed tissues [29].
iTregs are crucial for maintaining immune cell homeostasis, because if a T cell specific for
some food or commensal antigen does not become an iTreg and it differentiates in effector
T cell, then it can potentially induce severe inflammation such as colitis [30]. On the other
hand, development of all Tregs has to be precisely controlled, as they can also become a
double-edged sword by preventing anti-tumor [31] and anti-infection T cell responses [32].
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3.3 Dendritic cells
Dendritic cells are tree-like shaped cells (gr. dendron = tree) and were first described in
1973 by Ralph M. Steinman [33]. Soon it became clear that they share a lot of features with
Langerhans cells observed by Paul Langerhans five years earlier. DCs belong to a larger group
of cells called professional APCs which in addition to DCs include macrophages, Langerhans
cells and B cells [34, 35].
DCs consist of a functionally and developmentally diverse group of cells, which are able to
link innate and adaptive immunity. With numerous surface receptors of the innate immunity
DCs can efficiently take up antigens, process them, and present their peptides in context of
MHC molecules to the cells of the adaptive immune system. They also activate T cells by
expressing co-stimulatory molecules and provide additional information about the origin of
an antigen, in order to trigger a diverse spectrum of efficient protective responses [36].
What makes DCs special in antigen presentation is their potential for cross-presentation of
exogenous antigens in context of MHC class I molecules and therefore acting on CD8 cytotoxic
T cells. The latter has been shown to be crucial for immune response against viruses and
tolerance to self antigens [37, 38].
In addition to Steiman’s conventional DCs (cDCs) a second phenotypically and functionally
different group of DCs exist. These morphologically resemble plasma cells and are called
plasmacytoid DCs (pDCs). These cells produce large amounts of type 1 interferons in response
to viral infections [39], but they won’t be further discussed here.
cDCs orgin from hematopoietic stem cells derived common myeloid progenitors (CMPs)
or common lymphoid progenitors (CLPs), which were both shown to be capable of further
differentiation towards DC [40], but it has been published that under steady state conditions
most of DCs are derived from the myeloid lineage [41]. CMP differentiate via several pre-
cursors (granulocyte-macrophage precursor differentiate to macropage/DC progenitor, which
give rise to common DC precursor) to preDC and finally to cDC [42, 43], which are then
distributed all over the body: thymus, lymphoid organs, afferent lymphatics, nonlymphoid
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organs (intestinal cDCs), dermis (Langerhans cells) and peripheral blood [44, 45, 46, 47, 48].
3.3.1 Conventional dendritic cells subsets
cDCs, monocytes and macrophages form the mononuclear phagocyte system, a complex group
of cells with different, but specially in inflammation often overlapping, functional and pheno-
typical characteristics. cDCs are generally defined as CD45+, MHC class II+, CD11c+ cells,
which lack other lineage specific markers [49].
Especially in the mucosa of the intestinal tract it is hard to distinguish between cDCs
and macrophages, since gut resident macrophages also express CD11c [50] and high levels of
MHC class II molecules [51]. In this case even morphological analysis is not helpful because
intestinal macrophages express tight junction proteins and form a transepithelial dendritic
projections [52].
Therefore for the delineation of cDCs and macrophages some of additional markers like
Flt3 [53, 54], the chemokine receptor CCR7 [55], the zinc finger transcription factor zbtb46
[56], CD115 [57], CD64 [58] or F4/80 [59] are needed.
cDCs can be roughly separated according to their migration ability in tissue-migratory
cDCs and lymphoid organ-resident cDCs [60, 61]. Tissue-migratory cDCs migrate via afferent
lymph due to the up-regulation of the chemokine receptor CCR7 [55] to the T cell areas of
secondary lymphoid organs, where they stimulate naïve T cells [62]. Under inflammatory
conditions this trafficking is strongly increased [63]. In contrast lymphoid organ-resident
cDCs remain in lymphoid tissues [64].
The second separation of cDCs is based on their surface phenotypes and divides cDCs in
two main subsets: CD8+/CD103+ and CD11b+ expressing cells, which both are present in
lymphoid and non-lymphoid tissues [65].
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3.3.1.1 CD8+/CD103+ DCs
CD8+ expressing lymphoid-resident DCs were first described in murine lymphoid organs [46].
An equivalent subset in non-lymphoid tissues are migratory DCs expressing CD103+ integrin
[66]. CD8+/CD103+ DC subsets have a similar phenotype and transcriptional profile. Their
development is dependent on interferon regulatory factor 8 (IRF8), inhibitor of DNA binding
2 (Id2), nuclear factor interleukin 3 regulated (NFIL3) and basic leucin zipper transcription
factor ATF-like 3 (Batf3) transcription factors, where the absence of either of these leads to a
severe developmental deficiency [67, 68, 69, 70, 71]. They also share a unique transcriptional
fingerprint since only these two DC subsets express C-type lectin domain family 9 member
A (Clec9A) [72] and chemokine receptor Chemokine XC receptor 1 (XCR1) [73, 74]. In
addition they express C-type lectin cluster of differentiation 205 (CD205), a well described
endocytic recognition receptor for apoptotic and necrotic self, important in antigen uptake,
processing, presentation and antigen cross-presentation [75, 76]. Being able of processing
exogenous antigens and cross-presenting them in the context of MHC class I pathway, gives
these DC subsets the ability to activate CD8+ T cells and generate cytotoxic T cell immunity
against antigens associated with viral infection, intracellular bacteria, parasites and tumors
[77]. In order to effectively stimulate T cells, CD8+/CD103+ DCs respond to TLR signals
with a high level of bioactive IL-12p70 [78, 79], a cytokine involved in the initiation of the
Th1 immune response [80].
CD8+ and CD103+ DC subsets were therefore proposed to be very closely related if not
identical [74, 81], but there are also publications which reveal some differences between the
two subsets. CD8+ DC were published to express higher levels of TLR3 than CD103+ DCs
[82]. While a second study, published in 2014 [66], revealed even more differences. They have
shown that the two subsets differ in their ability to influence CD4+ T cell differentiation,
where the CD103+ subset is more potent in directing of T cells towards the Th17 phenotype,
due to its higher production of IL-1 and IL-6 cytokines upon stimulation. They demonstrated
that only CD103+ require GM-CSF for development and function, and that these two DC
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subsets differ in the expression of inflammasome components, where CD8+ express higher
levels of NLRP1a/b, NLRP3, NLRC4 and NLRP12, and CD103+ express higher levels of
NLRP6 and NLRP10.
3.3.1.2 CD11b+ DCs
CD11b+ DC subset is in comparison to CD8+/CD103+ DCs more diverse and less char-
acterized. Cells can be found in nonlymphoid tissue and in lymphoid organs except for the
thymus [65]. They are not efficient in cross-presentation, but due to the prominent MHC class
II machinery [75] and efficient production of IL-6 [83] and IL-23 [84], preferentially prime T
helper cells. Batf3-IRF8-Id2 independent CD11b+ DCs developmentally depend on interferon
regulatory factor 2 (IRF2), interferon regulatory factor 4 (IRF4), IKAROS, v-rel avian retic-
uloendotheliosis viral oncogene homolog B (RelB), neurogenic locus notch homolog protein
2 (Notch2) and recombining binding protein suppressor of hairless (RBP-J) (for review, see
[85]). CD11b+ DCs in the spleen can be separated in CD11b+Esamℎ𝑖 and CD11b+Esam𝑙𝑜𝑤
populations, where only the CD11b+Esamℎ𝑖 population is controlled by the Notch2 pathway
[86].
3.3.2 Intestinal DCs
The intestinal mucosa represents a huge epithelial surface, where the immune system en-
counters dietary antigens, commensal bacteria as well as potential pathogens. The selective
permeability of mucosa is crucial for nutrition digestion, absorption and waste disposal, but
represents a potential danger for pathogen entry. The intestine is a crucial site of innate and
adaptive immune regulation where pathogens may induce immune response, while destruc-
tive responses against food antigens and commensals must be prevented in order to avoid a
breakdown of intestinal homeostasis, which may lead to inflammatory bowel disease (IBD),
celiac disease or allergies [87, 88]. This fine tuning of immune responses is possible due to
the high plasticity of intestinal DCs which are equally equipped to induce regulatory and
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stimulatory immune responses.
Intestinal DCs consist of three phenotypically and developmentally distinct populations
which are located in the lamina propria of the small and the large intestine, peyers patches,
mesenteric lymph nodes (mLNs) and isolated lymphoid follicles [89]. In contrast to DCs
in lymphoid organs the intestinal DCs (MHCII+CD11c+CD64− [58]) are divided in three
subsets: CD103+CD11b−, CD103+CD11b+ and CD103−CD11b+ [90].
3.3.2.1 Origins and development of the intestinal DCs
Transmembrane integrin CD103 is an adhesion receptor that mediates retention of lympho-
cytes within epithelial tissues through binding to E-cadherin [91, 92]. CD103 does not seem
to be a marker of a particular DC lineage, but is most likely induced on CD11b+ and CD11b−
DCs during their residence within the intestine [90]. This belief is supported by the fact that
two CD103 expressing DC populations have different developmental origins, require distinct
transcription factors and display unique gene-expression profiles [93]. With use of Zbtb46-
DTR mice (transcription factor selectively expressed by cDCs [94]) it has been demonstrated
that some of CD103+CD11b+ cells actually derive from monocytes, since diphtheria toxin
treatment reduced this population only by 50 %, while CD103+CD11b− were almost com-
pletely absent. Partial monocyte origin of CD103+CD11b+ DCs was confirmed in the same
study with mouse model where monocytes and monocyte derived cells were specifically ab-
lated (diphtheria toxin treated Lysm𝐶𝑟𝑒 x Csf1r𝐿𝑠𝐿−𝐷𝑇𝑅 mice) [95].
CD103+CD11b− are closely related to cross-presenting CD8+ lymphoid-resident DCs. They
express the chemokine receptor XCR1 [73, 74] and lectin Clec9a [96], while for their develop-
ment they require Batf3, Id2, IRF8 and B-cell lymphoma 6 (Bcl-6) [81, 70, 97, 98].
On the other side CD103+CD11b+ intestinal DCs share features with CD11b+ lymphoid-
resident DCs. These cells express lectin C-type lectin domain family 4 member A (Clec4A) [75]
and signal regulatory protein-𝛼 (SIRP𝛼) [83]. It was published that they are developmentally
dependent on Notch2, RBP-J, PR domain zinc finger protein 1 (PRDM1) (also known as
3.3 Dendritic cells 15
Blimp1) and partially on IRF4 [99, 97]. Since in IRF4-deficient mice CD103+CD11b+ DCs
are approximately 50 % reduced in the intestine and almost completely absent in mLNs [83].
The last intestinal CD103−CD11b+ DCs subset with intermediate CX3CR1 expression rep-
resent a poorly defined heterogeneous group of cells which, for a long time, was not clear if
they are really bona fide DCs or instead macrophaghes [70]. Gautier et al. described CD64
as a good marker for discrimination between macrophages and DCs, as DCs are CD64− [100].
In contrast to CD103+ DCs, which develop from pre-DCs, CD103−CD11b+CX3CR1𝑖𝑛𝑡 derive
from Gr1+ monocytes in a GM-CSF and Flt3 controlled manner [101, 102, 70]. The current
opinion is that cells expressing intermediate levels of CX3CR1 appear to be distinct from
CX3CR1ℎ𝑖 macrophages, because they depend on cDCs specific transcription factor Zbtb46
[56], express high levels of CCR7, are efficient in priming naïve T cells and continuously
migrate from tissue to the draining mLNs, which is an important functional feature to distin-
guish DCs from macrophages [103]. Transcription factors required for CD103−CD11b+CD64−
DCs development remain to be fully assessed, because old studies did not separate these cells
from CD103−CD11b+CD64+ macrophages. Surprisingly, intestinal CD103−CD11b+ DCs are
not reduced in IRF4 deficient mice, suggesting that they are not related to CD103+CD11b+,
or that IRF4 is needed for CD103 up-regulation on CD11b+ DCs [84].
3.3.2.2 Tolerogenic and immunogenic intestinal DC subsets
Intestinal CD103+ DCs take up bacterial antigens from the gut lumen [104, 105] or from
CX3CR1ℎ𝑖 non-migratory macrophages [106] and continuously migrate to mLNs where they
prime naïve T cells or induce tolerance [103]. The ability to induce Treg cells from naïve T cells
with TCR specific for harmless dietary antigens and commensal flora is of particular benefit
in the intestine. Intestinal CD103+ DCs were shown to be superior in inducing Foxp3 Treg
cells, due to their high expression level of enzyme aldehyde dehydrogenase, which converts
vitamin A into retinoic acid, and their ability to activate latent TGF-𝛽 [107, 108]. Retinoic
acid is important in the process of imprinting gut homing CCR9 and 𝛼4𝛽7 receptors on newly
induced Tregs or effector T cells [109, 110].
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A study which compared CD103− and CD103+ DCs revealed that the CD103+ subset
express higher levels of transforming growth factor-𝛽2 (TGF-𝛽2), tissue plasminogen activator
and latent TGF-𝛽-binding protein 3. Proteins which have all been shown to be important
for efficient secretion, appropriate localization and conversion of latent TGF-𝛽 into its active
form [111, 108].
However CD103+ DCs were shown not to be hard-wired to induce tolerance, they can adapt
to environmental conditions and in inflammation rather induce IFN-𝛾 producing CD4+ T
cells than Tregs. Experiments performed in colitic mice have shown that CD103+ DCs in
inflammation lower their expression of tgfb2 and aldh1a2, which dampens their tolerogenic
properties [112]. This means that there is no exclusively tolerogenic DC subset, but this result
rather supports the observation that phenotypically immature DCs induce tolerance, while
DCs which detected a danger signal in the form of so called "pathogen associated molecular
patterns" become mature, and mature DCs can regardless of their subset induce immunity
[12].
Nevertheless, for a long time it was not clear which subset of CD103+ DCs is responsible
for Treg cell induction in the periphery. Mice without one or even both CD103+ DC subsets
were long lived and did not show any autoimmunity [113, 81, 83]. The ablation of both
CD103+ DC subsets resulted in significantly reduced numbers of lamina propria Tregs, while
mLN Tregs were not affected [113]. However, when only CD103+CD11b− DCs were missing
this had no effect on number of Tregs [81]. The same result was found with the ablation of
CD103+CD11b+ DC subset [113, 83]. All these results seem surprising, but it is important
to know that most of these studies analyzed only total Foxp3 Treg cells and not specifically
iTreg cells. There was only one study which shows that the ablation of CD103+CD11b+ DCs
does not effect total Treg number, whilst it causes a minor, albeit significant, increase in the
proportion of Helios+ Foxp3+ cells within the colon [83].
Only recently in 2016 a study by Esterhazy et al. offered a clear answer via specific
depletion of either CD103+CD11b− or CD103+CD11b+ DC subset, followed by analysis of
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oral tolerance and Treg cell induction. Targeting CD103+CD11b− DCs partially prevented the
generation of iTregs but did not effect oral tolerance, indicating the ability of the remaining
DCs to compensate and ensure oral tolerance. On the other side, the CD103+CD11b+ DC
subset was shown to be rather inefficient in Treg induction. Transcriptome analysis revealed
that the main tolerogenic CD103+CD11b− DC subset expresses the highest levels of Aldh1a2
(encoding retinaldehyde dehydrogenase RALDH2), Tgfb2 (encoding cytokine TGF-𝛽2) and
Itgb8 (encoding integrin 𝛽8), all enzymes crucial for Treg induction and imprinting of gut
homing. The CD103+CD11b+ DC subset was shown to have a lower Treg inducing gene
signature with other gene isoforms [114].
A subpopulation of intestinal CD103+CD11b+ DCs, which represent the majority of DCs in
the small intestine [115], was shown to have an important role in the induction of inflammatory
intestinal Th17 cells in steady state [86, 113, 83] and upon activation also Th1 cells [103, 116].
Specific ablation of CD103+CD11b+ cells resulted in a greatly reduced frequency of Th17
cells in lamina propria [86, 113, 83], while they were not affected in mice which are lacking
CD103+CD11b− DCs [113]. It was shown that CD103+CD11b+ DCs drive mLN Th17 cell
differentiation in an IL-6 dependent way [83].
Most CD103− DCs in lamina propria express CD11b and have a more inflammatory phe-
notype already in steady state, due to higher expression of TLR2, TLR3 and T-bet [108].
This phenotype makes them efficient in inducing differentiation of IFN-𝛾 and IL-17-producing
effector T cells, even in lack of proper stimulation [103]. It has been shown that they ex-
press substantially higher levels of an IL-23p19 messenger ribonucleic acid (mRNA) than
CD103+ cells and upon activation produce enhanced levels of IL-6 and TNF-𝛼 [108, 117].
CD103−CD11b+ DCs migrate to mLNs, prime naïve T cells and imprint them with a gut
homing phenotype. Newly formed effector T cells can therefore migrate to the gut and mount
an effective defense against intestinal pathogens [103].
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3.4 CD40 signaling in DCs
The CD40 surface receptor is a transmembrane glycoprotein, with a molecular mass of 48 kDa,
initially described on B cells and later shown to be expressed also by DCs, follicular DCs,
monocytes, epithelial cells, endothelial cells, hematopoietic progenitor cells and carcinomas
[118, 119, 120, 121]. CD40 ligand (CD40L) has a molecular mass of 33 kDa and is mostly
expressed by activated CD4+ T cells [119]. However, DCs [122], B cells [123], basophils
[119], eosinophils [124] and mast cells [125] have also been shown to express CD40L. CD40
crosslinking in B cells is important for cell proliferation [118, 126, 127] and immunoglobulin
class switching [128], while its role in DCs is less well understood. Several studies have
reported that CD40 signaling improves the antigen presenting potential of stimulated DCs
with an up-regulation of MHC class II and co-stimulatory molecules CD80 and CD86 [129,
130, 131]. CD40L induces trimeric clustering of CD40 molecules on DCs which results in the
activation of a non-canonical NF-𝜅B pathway [132] and triggers the production of IL-12-p40
and IL-6 cytokine [133, 134]. However, another study has shown that CD40 signaling alone is
not sufficient for complete maturation of DCs, because it only induces secretion of IL-12p40,
but not its bioactive heterodimer IL-12p70. While it also does not lead to an increase of CD40
expression [135], which is a marker for the discrimination between immature and mature DCs
[136]. Therefore other studies suggest that the complete maturation of DCs requires the
combination of CD40 signaling with innate microbial priming signals [137, 138, 139].
Certainly there is some inconsistency between studies which probably originates from the
design of experiments. An anti-CD40 monoclonal antibody (mAb) can be applied in vitro or
in vivo. Each method has some advantages and disadvantages. Studies mentioned above were
performed in vitro where growth factors, serum and plastic materials could have influenced
cultured cells. It was published that DCs respond to materials with receptors of innate
immunity what results in their maturation and that different materials have different effects
on DC maturation [140, 141]. Therefore, a mature phenotype of DCs in some studies might
have actually be induced by plastic material or other substances but not only by activation
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trough the CD40 pathway.
The other approach are in vivo studies, where anti-CD40 is injected in mice and the ef-
fects on DCs are studied afterwards. A group lead by Fiona Powrie has shown that CD40
stimulation down-regulate CD103 expression on sorted DCs in vitro and could show simi-
lar effects in vivo, when Rag−/− mice were injected with the anti-CD40 antibody and had
less CD103+MHCII+ cells in spleens and developed wasting disease with colitis [142]. Since
CD103+ DCs are supposed to be the most tolerogenic DCs subset important for induction
of peripherial iTregs [108, 111], their depletion with a single injection of anti-CD40 antibody
seemed to be a promising way to study their role. However, this method is not ideal, as
CD40 is not expressed only on DCs but also on many other cell types [118, 119, 120, 121].
Therefore, injection of anti-CD40 antibody has a systemic effect and it can not be concluded
that all observed changes are only due to triggering of the CD40 pathway in DCs. This
concern was supported by one study showing that CD40 ligation triggers a B cell mediated
necroinflammatory response in the liver [143]. It is true that experiments from Powrie et
al. [142] were performed in Rag−/− animals, which do not have B and T cells, but anyway
the anti-CD40 effect on other cells like epithelial and endothelial cells can not be excluded.
Therefore, the loss of CD103+ DCs and observed DC maturation after anti-CD40 treatment
could be a secondary effect of a cytokine storm from other cell types.
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3.5 CD4+ effector T cells
Naïve CD4+ T cells develop in effector T cells after encountering antigens presented in the
context of MHC class II molecule on APCs. Depending on cytokines present in the microenvi-
ronment during the T cell receptor mediated activation process, naïve T cell can differentiate
into several different subsets of T helper cells. This T cell subset provide help to other cells
of the immune system with secreting cytokines, which orchestrate immune responses to be
efficient for specific pathogens. T helper cells are crucial players of the adaptive immune
system, they provide help to B cells and cytotoxic T cells and maximize bactericidal activity
of macrophages [144, 145, 146].
Helper T cells can be subdivided into several subsets [147]. Th1 and Th2 cells were dis-
covered in 1986 [148] as subsets with different functions responsible to clear different types
of pathogens, expressing a different set of cell surface molecules and possess a characteris-
tic cytokine signature dependent on specific distinct transcription factors. Th1 cells were
shown to provide protection against intracellular pathogens [149, 150, 151] and are involved
in antitumor immunity [152], while their exaggerated response against self antigens can re-
sult in an autoimmunity [153]. Th1 cell differentiation requires cytokine IL-12 and depends
on transcription factors T-bet, STAT1 and STAT4 [154]. T-bet controls the expression of
Th1 signature cytokine INF-𝛾 [154], while Th1 pattern of cytokine production additionally
includes TNF-𝛼, TNF-𝛽 and IL-2 [148, 155]. By contrast, differentiation of Th2 cells require
cytokine IL-4 and depends on transcription factors STAT6 and GATA-3. The master reg-
ulator GATA-3 controls all of the cytokines which form the so called Th2 signature: IL-4,
IL-5, IL-9 and IL-13 [156]. Th2 cells mediate eosinophil activation and protective humoral
immunity against extracellular parasites, while their overreaction has been connected with
different forms of allergic responses [157, 158, 159].
Almost 20 years after Mosmann and Coffman divided T helper cells into two distinct
subsets, Harrington et al. [160] described Th17 cells, a third subset of T helper cells involved in
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protection against various especially extracellular bacteria infections, which are also involved
in many autoimmune diseases [161]. These cells differentiate independently from transcription
factors needed for Th1 or Th2 cell development [160] and produce IL-17A, IL-17E (IL-25),
IL-17F, IL-21 and IL-22 [162, 163, 164, 165, 166, 167]. However, retinoic acid receptor (RAR)-
related orphan receptor gamma t (ROR𝛾t) has been shown to be the central transcription
factor responsible for Th17 cell polarization and IL-17 transcription [168], while a cytokine
pattern required for induction and expansion of Th17 cells seems to be very complex and will
be discussed bellow.
Up to now additional CD4 T-cell subsets have been identified: iTreg cells, follicular helper
T cells, Th9 cells, Th22 cells and ThGM cells [155, 169, 170].
3.5.1 Pathogenic and protective Th17 cells
Th17 cells in peripheral organs do not have a homogeneous function, as on one hand they
were shown to confer host protection against extracellular bacteria, mycobacteria and fungal
infections [171], but they are also involved in multiple inflammatory and autoimmune diseases
[172]. Apparently the cytokine milieu at the side of inflammation can be responsible for the
various functions of Th17 cells including their pathogenicity.
Differentiation of effector Th17 cells from naïve CD4+ T cells requires TGF-𝛽1 and proin-
flammatory cytokine IL-6 [173]. Exposure to IL-6, which induces IL-23 receptor expression,
is necessary for initial Th17 lineage commitment, because TGF-𝛽1 alone would result in a
differentiation of iTreg cells [174]. Th17 cells differentiated that way are not pathogenic,
but rather protective, due to their co-production of anti-inflammatory IL-10 [175]. Further
exposure to IL-23 results in a pathogenic expression signature, which in addition to T-bet,
the master regulator of Th1 cells, includes GM-CSF, IL-23R and IL-7R [176, 163]. IL-17
expression of Th17 cells was shown to be transient in some inflammatory settings, because
cells after IL-23 conversion can stop expressing IL-17, acquire the ability to express IFN-𝛾
and are therefore called ex-Th17 cells or Th1-like cells [177]. However, the pathogenic Th17
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cell phenotype can also be induced in an alternative TGF-𝛽1 independent way, if they are
exposed to a combination of IL-1, IL-6 and IL-23 or TGF-𝛽3 and IL-6 [178, 176].
Changes in intestinal microbiota and in diet were shown to alter normal cytokine regulation
and affect Th17 differentiation, which offers an explanation for the increased incidence of Th17
induced autoimmune diseases in the literature [179].
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3.6 Modeling human diseases in mice
The fact that humans and mice share about 95 % of protein coding genes makes mice a
powerful model for studying human biology and disease [180]. Inbred mouse strains are ge-
netically nearly identically, since this is essential for reproducibility of research experiments
[181]. Short generation time, short life span, being easy to breed and progress in conventional
transgenic and gene knockout technologies have enabled modeling of human diseases in exper-
imental mice [182]. Since mouse strains are genetically and phenotypically diverse, it is not a
surprise that they demonstrate variable susceptibility to different diseases [183, 184, 185, 186].
Two of the most common used strains, also used in this project, are BALB/c and C57BL/6
mice. BALB/c are white albino mice with a H2𝑑 MHC haplotype, developed by H.J. Bagg
in 1913, while C57BL/6 are black with a H2𝑏 MHC haplotype, developed by C.C. Little in
1921.
3.6.1 Ulcerative colitis
Ulcerative colitis is a chronic relapsing and remitting autoimmune disorder where the large
intestine (colon) and rectum (end of colon) are chronically inflamed and ulcers that cause
crampy abdominal pain, frequent emptying of the colon and rectal bleeding may be formed
[187]. In the past, ulcerative colitis was considered a disease of the Western populations, but
in the last decades the incidence has dramatically increased also in other countries paralleling
changes in lifestyles and behavior [188, 189]. Risk factors for Ulcerative colitis consist from a
complex interaction between genetics, environment and microbiota [190]. By now there is no
cure for colitis, only a number of medical treatments with a goal to induce disease remission
and prevent long-term complications [191, 192, 193], therefore further studies are needed.
Mouse models are indispensable for examining the mechanistic details of the disease which
can lead to improvements of pre-clinical drugs and novel design of therapies [194].
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3.6.2 Mouse models of ulcerative colitis
Imitating ulcerative colitis in mouse models can contribute to a better understanding of the
disease and evaluate a number of potentially helpful therapies. Experimental colitis can be
induced with a bacterial infection and with the administration of irritant chemicals, while
some genetically manipulated mouse strains even develop colitis spontaneously [194]. The
chemical used most commonly for the induction of colitis is dextran sodium sulfate (DSS)
[195]. Other chemicals used to induce colitis are administrated intrarectally, such as hapten
oxazolone, diluted acetic acid or 2,4,6-trinitrobenzene sulfonic acid [196, 194, 197]. The most
commonly used bacterial options to trigger colitis are oral infections with gram-negative
Salmonella typhimurium or adherent invasive Escherichia coli [194].
Experimental colitis can also be induced immunologically by adoptive transfer of naïve
CD4+ T cells (CD4+CD45RBℎ𝑖𝑔ℎ or CD4+CD62L+ T cells) from healthy wild-type donor
mice into a syngeneic immunodeficient severe combined immunodeficiency (SCID) or Rag−/−
recipient, which results in wasting disease, diarrhea and in colonic inflammation [198, 199].
One of the earliest and by far most widely used gene-targeted models of experimental
colitis was described in IL-10 deficient mice, which develop spontaneous colitis and cecal
inflammation with inflammatory cell infiltration into lamina propria [200, 201]. Other com-
monly used gene-targeted colitis models are IL-7 transgenic mice [202], TCR𝛼 knockout mice
[203], Wiskott-Aldrich syndrome protein knockout mice [204], Mdr1a knockout mice [205],
IL-2 knockout mice [206] and Guanine nucleotide-binding protein G subunit 𝛼-2 knockout
mice [207].
3.6.3 The DC-LMP1/CD40 mouse model
To study CD40 signaling without systemic effects of anti-CD40 antibody injection our group
generated a model where only DCs receive constant CD40 signaling [208]. We used transgenic
mice expressing a conditional LMP1/CD40 transgene previously developed by a group led by
Ursula Zimber-Strobel [209]. This model is based on Latent membrane protein 1 (LMP1)
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molecule from the Epstein-barr virus, which was published to be a viral mimic of the CD40
molecule [210, 211]. However, LMP1/CD40 mice do not have a complete sequence for viral
LMP1 gene, but they express a fusion protein with transmembrane domain of LMP1 fused
to intracellular signaling domain of human CD40, which was previously shown to be suffi-
ciently conserved between two species to efficiently signal in mice [212]. This LMP1/CD40
construct has been inserted into the transcriptionally active ROSA26 locus and is protected
from expression by a loxP side flanked stop cassette upstream of the LMP1/CD40 coding
sequence. Therefore, by breeding this mice to a strain which expresses a Cre recombinase,
the stop cassette is removed genetically and transcription of the LMP1/CD40 fusion protein
can take place.
In the present study we use mice expressing Cre recombinase under control of the CD11c
promotor (Itgax-cre mice[213]) leading to expression of the LMP1/CD40 fusion protein se-
lectively in CD11c positive cells, mostly DCs and macrophages. As shown by previous pub-
lications, LMP1/CD40 fusion proteins self-aggregate in cell membrane and deliver a ligand-
independent constitutive CD40 signal to cells which express the construct [214, 215]. In the
context of the CD11c Cre transgene all DCs receive a constitutive CD40 signal.
CD40 signaling was previously connected with the maturation of DCs [129, 130, 131] and
since mature DCs are more prone to induce immunity than tolerance [12], DC-LMP1/CD40
mice develop severe fatal colitis (Fig.3.1 A). Only recently we have published that mice with
constitutive triggering of the CD40 signaling in DCs show reduced frequencies of tolerogenic
CD103+ DCs in lamina propria (Fig.3.1 B) and in mLNs, that results in a strong reduction of
iTregs cells (Fig.3.2 A), increased frequency of intestinal Th1 and Th1/Th17 cells (Fig.3.2 B)
and consequently in fatal colitis-like phenotype [208]. However, we also show that development
of colitis depends on B and T cells, since RAG−/− DC-LMP1/CD40 mice show long-term
survival (Fig.3.1 A) and that only CD40 signaling is not enough for colitis development, since
DC-LMP1/CD40 animals treated with a mixture of antibiotics (ABX) also show long-term
survival (Fig.3.1 A) and no colon inflammation (not shown) [208]. All these observations from
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DC-LMP1/CD40 mouse model support the in vitro observations from other studies, which
have shown that CD40 signaling alone is not sufficient for complete maturation of DCs [135]
and that for this additional bacterial signals are needed [137, 138, 139].
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Figure 3.1: DC-LMP1/CD40 animals develop fatal T cell, B cell and bacteria de-
pendent colitis and show reduced frequencies of CD103+ DCs. A) Kaplan-Meier plot
showing the survival of control (Ctr) and untreated or ABX-treated DC-LMP1/CD40 animals
on C57BL/6 and RAG−/− background (n ≥ 6). Figure is adapted from Figure 2 in our re-
cently published paper [208]. B) DC subsets in the LP were analyzed. Cells were gated on
live, CD45+CD11c+MHCII+CD64− cells from control, ABX treated or Rag1−/− mice. Rep-
resentative FACS plots are shown, numbers indicate frequency of DC subsets and bar graphs
show absolute numbers per colon. Shown are representative results from at least 2 independent
experiments with similar outcome (n = 3). Figure is adapted from Figure 3 in our recently
published paper [208].
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Figure 3.2: Severely impaired iTreg induction and breakdown of T cell toler-
ance in DC-LMP1/CD40 animals. A) Single cell suspension of LP was analyzed for
Tregs. Shown are representative FACS-plots of FoxP3+ Tregs found in the LP pre-gated on
single, live, CD45+CD3+CD4+CD25+FoxP3+ and in the next step subdivided into nTregs
(ROR𝛾t−Helios+) and iTregs (ROR𝛾t+Helios−). Shown is one representative experiment of
three with similar outcome (n = 3). Figure is adapted from Figure 4 in our recently published
paper [208]. B) T cell functionality was analyzed by stimulating single cell suspensions with
PMA/Ionomycin and subsequently staining cells intracellular for the production of IL-17 and
IFN-𝛾. Shown are representative FACS-plots with indicated frequencies for LP (gated on single,
live, CD45+CD3+CD4+) and mLNs (gated on single, live, CD3+CD4+) as well as pooled statis-
tics from more than 5 experiments (n = 14-18). Figure is adapted from Figure 5 in our recently
published paper [208].
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3.7 Aim of the thesis
DCs represent a crucial link between innate and adaptive immunity. Depending on maturation
status and due to their high level of plasticity, they can induce regulatory or stimulatory
immune responses. Our lab has recently been extensively studying the DC-LMP1/CD40
mouse model in which DCs received ligand-free constant CD40 signaling. Just recently we
have published that constitutively CD40 triggered DCs lack the intestinal tolerogenic CD103+
DC sub-type. As a consequence strong reduction of iTregs was observed leading to fatal colitis
which dependent on the presence of commensals and was caused by increased frequencies of
intestinal Th1 and Th1/Th17 cells [208].
The goal of this study was to examine how mouse strain background influences colitis
susceptibility, since we observed that only DC-LMP1/CD40 mice on C57BL/6 genetic back-
ground developed fatal colitis, while mice carrying the same genetic construct, but having
BALB/c or F1 (C57BL/6 x BALB/c) mixed genetic background, did not develop intestinal
inflammation. To this end we analyzed the immune phenotypes of transgenic mice in the dif-
ferent backgrounds more thoroughly and compared the frequencies of relevant immune cells
as well as their activation, maturation status and cytokine milieus. The goal was to get a
more detailed picture of DCs supporting or suppressing mechanisms in the intestine.
4 Material and Methods
4.1 Materials
4.1.1 Devices
Analytic scale (Adventurer, Ohaus Corp., Pine Brooks, NJ, USA), automatic pipettors (Inte-
gra Biosciences, Baar, Switzerland), bench centrifuge (Centrifuge 5415 D, Eppendorf, Ham-
burg, Germany), cell counter (CASY cell counter and analyzer, OMNI life science, Bremen,
Germany), centrifuge (Rotixa RP, Hettich, Tuttlingen, Germany), chemical scale (Kern, Alb-
stadt, Germany), ELISA-reader (𝜈max kinetic microplate reader, Molecular Devices, Biber-
ach, Germany), tissue homogenizer (FastPrep-24, MP Biomedicals, Santa Ana, CA, USA),
flow cytometer (FACSCalibur, FACSCantoII and FACSAria, FACSAria Fusion, BD, Heidel-
berg, Germany), incubator (Hera cell, Heraeus Kendro Laboratory Products, Hanau, Ger-
many), laminar airflow cabinet (Heraeus, Hanau, Germany), magnetic stirrer (Ika Labortech-
nik, Staufen, Germany), PCR-machine (Biometra, Goettingen, Germany), pH-meter (Ino-
lab, Weilheim, Germany), pipettes (Gilson, Middleton, WI, USA), power supply (Amersham
Pharmacia, Piscataway, NJ, USA), Qubit Fluorometer (Invitrogen, Carlsbad, CA, USA),
real-time PCR machines (CFX96 Real Time System, BIO-RAD, Hercules, CA, USA; Light-
Cycler 480 System, Roche Diagnostics Deutschland, Mannheim, Germany), vacuum pump
(KNF Neuberger, Munzingen, Germany), vortex-Genie2 (Scientific Industries, Bohemia, NY,
USA), water bath (Grant Instruments Ltd., Barrington Cambridge, UK).
4.1.2 Consumables
BD Microtainer BD, Franklin Lakes, NJ, USA
Disposable cell strainer (100 𝜇m nylon) Falcon a Corning Brand,
One Riverfront Plazza, Corning, USA
Disposable injection needle (26 G x 1/2”) Terumo Medical Corporation, Tokyo, Japan
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Disposable syringe (1+5 ml) Reaction Braun, Melsungen, Germany
Disposable glass pasteur pipettes (230 mm) VWR International bvba, Leuven, Belgium
FrameStar 480/96 for Roche Lightcycler 480 4titude Ltd, Berlin, Germany
Laboratory gloves Latex Gentle Skin Grip Meditrade GmbH, Kiefersfelden, Germany
Lysing matrix tubes (matrix A) MP Biomedicals Germany GmbH,
Eschwege, Germany
Petri dish (94 x 16 mm) Greiner Bio-One GmbH, Frickenhausen,
Germany
PCR strips tubes (0.2 mL) VWR International, West , Belgium
Qubit assay tubes (0.5 mL) Life technologies, Eugene, Oregon, USA
Reaction container 1.5 ml and 2 ml Eppendorf, Hamburg, Germany
Reaction container 5 ml (FACS) BD, Franklin Lakes, NJ, USA
Reaction container 15 ml and 50 ml Greiner, Frickenhausen, Deutschland
Serological pipette, sterile (10 ml) Greiner Bio-One GmbH, Frickenhausen,
Germany
TipOne filter tips (10 𝜇l, 200 𝜇l, 1000 𝜇l) STARLAB GmbH, Hamburg, Germany
Tissue culture plates (96 wells-U, sterile) VWR International bvba, Leuven, Belgium
4.1.3 Chemicals
Unless stated otherwise, chemicals were purchased from Merck (Darmstadt, Germany), Roth
(Karlsruhe, Germany) or Sigma-Aldrich (St. Louis, MO, USA). All buffers and solutions were
prepared using double distilled water.
4.1.4 Buffer and media
ACK: 8.29 g NH4Cl
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1 g KHCO3
37.2 mg Na2EDTA
H2O ad 1 L
pH 7.4
Cresol red buffer: 250 mM KCl
50 mM Tris-HCl (pH 8.3)
43 % Glycerol
2 mM Cresol red
7.5 mM MgCl2
FACS buffer: PBS
2 % FCS
0.01 % NaN3
GM-CSF medium: IMDM
10 % FCS
500 mM β-mercaptoethanol
100 U/ml Penicillin
100 g/ml Streptomycin
5 ml Glutamin
10 ml GM-CSF
HBSS: 137 mM NaCl
5.4 mM KCl
0.25 mM Na2HPO4
0.1 g glucose
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0.44 mM KH2PO4
1.3 mM CaCl2
1.0 mM MgSO4
4.2 mM NaHCO3
HBSS-EDTA: HBSS
8 % FCS
10 mM EDTA
10 mM HEPES
PBS: 137 mM NaCl
2.7 mM KCl
10 mM Na2HPO4
pH 7.4
50x TAE buffer: 242 g Tris-HCl
57.1 ml 100 % acetic acid (v/v)
100 ml 0.5 M EDTA (pH 8.0)
H20 ad 1 L
10x Gitocher: 670 mM Tris pH 8.8
166 mM NH
65 mM MgCl2
0.1 % gelatin
1x Gitocher buffer: 5 µl 10x Gitocher buffer
2.5 µl 10 % Triton X-100 (v/v)
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0.5µl β-mecaptoethanol
3 µl proteinase K (10 mg/ml)
39 µl H2O
4.1.5 Antibodies
epitope conjugate clone manufacturer
CD3 PE-Cy7 145-2C11 eBioscience
PerCP 145-2C11 BD Bioscience
FITC 145-2C11 eBioscience
Biotin 145-2C11 BioLegend
CD4 APC-Cy7 GK1.5 BioLegend
BV 510 GK1.5 BioLegend
CD8 BV 53-6.7 BioLegend
CD11b APC-eFlour780 M1/70 eBioscience
CD11c PE-Cy7 N418 BioLegend
CD16/CD32 2.4G2 BD Bioscience
CD19 Biotin 1D3 BD Pharmingen
CD25 PC61.5 PerCP-Cy5.5 eBioscience
CD40 Biotin HM40-3 eBioscience
CD44 Pacific Blue IM7 BioLegend
PerCP IM7 BD Bioscience
CD45 BV 421 30-F11 BioLegend
PerCP 30-F11 BioLegend
APC-eFluor780 30-F11 eBioscience
CD62L APC MEL-14 BD Bioscience
PE MEL-14 eBioscience
Continued on the next page.
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epitope conjugate clone manufacturer
CD64 APC X54-5/7.1 BioLegend
BV 421 X54-5/7.1 BioLegend
CD69 PE H1.2F3 BD Bioscience
PE-Cy7 H1.2F3 BioLegend
CD80 PE 16-10A1 BD Bioscience
CD86 PE GL-1 eBioscience
CD103 BV 421 M290 BD Horizon
PE M290 BD Bioscience
CD154 (CD40L) PE MR1 BioLegend
CD152 (CTLA-4) PE UC10-4F10-11 BD Pharmingen
CD197(CCR-7) PE 4B12 eBioscience
F4/80 PE-Cy7 BM8 eBioscience
FoxP3 eFlour660 FJK-16s eBioscience
Biotin FJK-16s eBioscience
Gata-3 eFlour660 TWAJ eBioscience
goat a-rabbit PE Life technologies
Helios FITC 22F6 eBioscience
IL-17A PE TC11-18H10.1 BD Bioscience
PE-Cy7 TC11-18H10.1 BioLegend
IFN-g APC XMG1.2 eBioscience
FITC XMG1.2 eBioscience
KI67 PE B56 BD Pharmingen
Ly6C FITC AL-21 BD Bioscience
PE-Cy7 AL-21 BD Bioscience
MHCII FITC M5/114.15.2 BioLegend
PerCP M5/114.15.2 BioLegend
Continued on the next page.
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epitope conjugate clone manufacturer
Rat IgG2a kappa PE RTK2758 BioLegend
Rat IgG2b kappa eFlour660 eB149/10H5 eBioscience
RORgt PE AFKJS-9 eBioscience
PerCP B2D eBioscience
Streptavidin BV 421 BioLegend
PerCP BD Bioscience
Tbet PE-Cy7 eBio4B10 eBioscience
TCR-b FITC H57-597 eBioscience
PerCP M5/114.15.2 BioLegend
The agonistic anti-CD40 antibody (clone FGK4.5/FGK45, isotype rat IgG2a) for immuniza-
tions was purchased from Bio X Cell (West Lebanon, USA) where we also purchased the anti
mouse IL-1 beta (clone B122, isotype Armenian hamster IgG).
4.1.6 Oligonucleotides
All oligonucleotides were purchased from MWG-Biotech AG (Ebersbach, Germany).
target primer name sequence application probe
IL1a IL1a qPCR_f TTGGTTAAATGAC-
CTGCAACA
qPCR 52
IL1a qPCR_r GAGCGCTCACGA-
ACAGTTG
IL1b IL1b qPCR_f TGTAATGAAAGAC-
GGCACACC
qPCR 78
Continued on the next page.
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target primer name sequence application probe
IL1b qPCR_r TCTTCTTTGGGTA-
TTGCTTGG
IL-6 IL-6_f GAAGGGCACTGCA-
GGATAGA
qPCR 12
IL-6_r TCCCCAGAGTGTG-
GCAGT
IL-12p35 IL-12 p35_f CCAGGTGTCTTAG-
CCAGTCC
qPCR 62
IL-12 p35_r GCAGTGCAGGAAT-
AATGTTTCA
IL-23p19 IL-23_f2 ATAGCCCCATGGA-
GCAACTT
qPCR 25
IL-23_r GCTGCCACTGCTG-
ACTAGAA
LMP1-
CD40
LMP qPCR_f GGATGTATTACCA-
TGGACAACG
qPCR 139
LMP qPCR_r TTGATCTCCTGGG-
GTTCCT
HPRT HPRT1_f TCCTCCTCAGACC-
GCTTTT
qPCR 95
Continued on the next page.
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target primer name sequence application probe
HPRT1_r CCTGGTTCATCAT-
CGCTAATC
Cre RO334 GGACATGTTCAGG-
GATCGCCAGGCG
genotyping
RO335 GCATAACCAGTGA-
AACAGCATTGCTG
LMP1-
CD40
HL15 AAGACCGCGAAGA-
GTTTGTCC
genotyping
HL54 TAAGCCTGCCCAG-
AAGACTCC
HL152 AAGGGAGCTGCA-
GTGGAGTA
IL1b IL1beta2_f TTTCCTCCTTGCC-
TCTGATG
sequencing
IL1beta2_r ATGTGCTGGTGCT-
TCATTCA
4.1.7 Mouse strains
All mouse strains were breed and kept in the Institute for Immunology at the LMU Munich.
The following mouse strains have been used in this work.
BALB/c
BALB/c is an inbred mouse strain developed by H.J. Bagg in 1913. Their coat is white
(albino) and they have the H2𝑑 MHC haplotype.
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C57BL/6
C57BL/6 is an inbred mouse strain developed by C.C. Little in 1921. Their coat is black
and they have the H2𝑏 MHC haplotype.
CD11c-Cre
The CD11c-Cre mice strain was produced in the Lab of Boris Reizis. They expresses the
Cre recombinase under control of the CD11c promotor [213]. This mouse allows the deletion
of floxed allels in DCs and other CD11c-expressing cells. Mice were kept on the C57BL/6
and BALB/c genetic background.
DC-LMP1/CD40
To obtain DC-LMP1/CD40 animals, CD11c-Cre mice were crossed with LMP1/CD40 mice
[209]. The latter mouse strain carries the knock-in of the LMP1/CD40 gene which is preceded
by a floxed stop-codon into the ROSA26 locus. The cre-mediated excision of the stop codon
then leads to the constitutive expression of the fusion-protein between LMP1, derived from
the Epstein-Barr-Virus (EBV), and the intracellular signaling domain of human CD40. The
LMP1 domain anchors the protein in the plasma membrane and at the same time leads to a
multimerization, which in turn leads to signaling by the CD40 molecule.
DC-LMP1/CD40 mice have been breed on different genetic backgrounds. On pure C57BL/6
genetic background, on pure BALB/c genetic background and on mixed genetic background
between C57BL/6 and BALB/c mouse strain (named F1 DC-LMP1/CD40). For the purpose
of single nucleotide polymorphism (SNP) study F1 DC-LMP1/CD40 mice were intercrossed
to obtain a genetically heterogeneous generation named F2 DC-LMP1/CD40.
Rag1−/−
Rag1−/− mice are unable to form B and T cells due to a defect in the V(D)J-recombination
machinery [216].
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4.2 Methods
4.2.1 Immunological and cell biology methods
4.2.1.1 Harvesting of organs and single cell preparation
Animals were euthanized in a CO2 chamber. Mice were fixed with needles on a styrofoam
pad, disinfected with 70 % ethanol and cut open. Using scissors and fine tweezers organs
were removed and placed into phosphate buffered saline (PBS). Spleen and lymph nodes
were smashed through a 100 𝜇m cell strainer and washed with ice cold PBS. Red blood
cells were lyzed using 1 ml of ACK buffer for 5 min at room temperature. Samples were
washed once again, counted with the CASY-counter (OMNI life science, Bremen, Germany)
and stored on ice for further analysis.
To analyze cells from the lamina propria, the colon was removed, the fecal matter cleaned
away, and then the colon was opened longitudinally and cut into ca. 5 mm long pieces. The
pieces were then incubated with HBSS-EDTA for 10 min on a shaker at 37∘C in order to
remove epithelial cells. In the next step, the pieces were digested once for 30 min and then
again twice for 20 min with a mixture of Collagenase IV (157 Wuensch units/ml, Worthing-
ton), DNAse I (0.2 mg/ml) and Liberase (0.65 Wuensch units/ml, both from Roche). The
supernatant was collected after each step of digestion and cells were always washed with PBS.
Collected cells were enriched for immune cells with Percoll gradient centrifugation. For this,
cells were resuspended in 40 % Percoll and this solution was underlayed with a 80 % Percoll so-
lution using a glass pasteur pipete. This mixture was than centrifuged for 20 min at 1800 rpm
at 4∘C without break. Cells at the interphase were collected, washed once, counted using the
CASY-counter (OMNI life science, OMNI life science, Bremen, Germany) and stored on ice
for further analysis.
4.2 Methods 40
4.2.1.2 Flow Cytometry staining
For flow cytometric analysis, 2·106 cells per staining were plated into a 96 well plate. Cells
were stained for 20 min at 4∘C in the dark in 50 𝜇l of antibody mix made with a fluorescence-
activated cell sorting (FACS) buffer. With titration, optimal dilution for each antibody has
been tested. After the incubation, the cells were washed once with 150 𝜇l FACS buffer and
than directly acquired at the FACS.
For CCR7, extracellular antibody staining cells were stained for 15 min at 37∘C in the dark
in 50 𝜇l of antibody mix made with a FACS buffer.
Samples stained with a biotinylated antibody were then stained with fluorescent labeled
streptavidin, also in a volume of 50 𝜇l, at 4∘C in dark for 20 min.
For intracellular stainings, cells were fixed and permeabilized after they were stained for
all extracellular markers. Fixation was 30 min long and performed with a Cytofix/Cytoperm
kit (BD, Heidelberg, Germany) according to the protocol provided by manufacturer. After
washing, cells were stained for intracellular markers for additional 30 min.
For the intranuclear staining of FoxP3, T-bet and Helios, cells were washed once and then
resuspended in 200 𝜇l 1x Fixation/Permeabilization solution (eBioscience, San Diego, CA,
USA) for 20 min at 4∘C in the dark. Cells were spun down, the supernatant was removed and
the cells were washed twice with 1x Permeabilization Buffer (eBioscience, San Diego, CA,
USA). Cells were then stained with a specific antibodies in 50 𝜇l Permeabilization Buffer for
30 min at 4∘C in the dark. Afterwards, cells were washed once and acquired at the FACS.
Acquisition was performed using a FACSCalibur or FACSCantoII. Data analysis was per-
formed using FlowJo version 8 and 10 (TreeStar, Ashland, OR, USA).
An advanced version of classical flow cytometry is cell sorting, a technique where a user-
defined individual cell population can be diverted from a fluidic stream and collected for
further analysis. Cell sorts were performed on a FACSAriaIII and a FACSAria Fusion (BD,
Heidelberg, Germany).
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4.2.1.3 In vitro T cell restimulation
To asses the cytokine secretion potential of a polyclonal T cell population, animals were
sacrificed and single cell suspensions prepared as described in section 4.2.1.1. 2·106 cells were
then plated into 96 well plates and stimulated for four hours at 23∘C with phorbol-12-myristat-
13-acetat (PMA) and ionomycin in a T cell-medium at a final concentration of 40 ng/ml and
1 𝜇g/ml respectively in the presence of 2 𝜇M Glogi-Stop (BD, Heidelberg, Germany), which
blocks protein secretion.
Afterwards, cells were washed twice with a FACS-buffer and stained for extracellular mark-
ers as described in section 4.2.1.2. To permeabilize cells, they were then resuspended in
150 𝜇l of BD Cytofix/Cytoperm (BD Bioscience) and incubated for 30 min at 4∘C in the
dark, washed once with Perm/Wash buffer (BD, Heidelberg, Germany) and stained for the
cytokines of interest for 30 min at 4∘C in the dark. Afterwards, cells were washed once again
and resuspended in a FACS buffer in which they were stored, at 4∘C, until acquisition.
4.2.1.4 Depletion of commensal microflora
To deplete as many commensal bacteria as possible, animals were provided a mixture of
ampicilin sodium salt (1 g/l), vancomycin hydrochloride (500 mg/l), neomycin sulfate (1 g/l)
and metronidazole (1 g/l) in the drinking water for 4 to 5 weeks [217].
4.2.1.5 Anti-IL-1𝛽 treatment
Five weeks old C57BL/6 DC-LMP1/CD40 animals, which have been treated with ABX to
prevent onset of colitis, were moved to cages containing feces from the rest of the mouse
facility for commensal bacteria repopulation and ABX treatment was stopped. At the same
time treatment of experimental mice with an anti-IL-1𝛽 antibody was started. 0.25 mg of
anti-IL-1𝛽 antibody (clone B122, isotype Armenian hamster IgG, Bio X Cell, West Lebanon,
USA) was injected twice per week intraperitoneally. The control mice were treated with an
isotype control antibody. Treatment lasted for 7 weeks. Afterwards animals were sacrificed
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and analyzed.
4.2.1.6 Magnetic cell sorting
To purify cell populations based on surface marker expression, magnetic cell sorting (MACS,
Miltenyi Biotec) was employed. There are two possible methods for magnetic-activated cell
sorting (MACS): labeling the population of interest (positive selection) or labeling of all
other cells (negative selection). This method is based on the use of monoclonal antibodies
that are conjugated to superparamagnetic microbeads. After labeling, cells were applied to a
column that has been placed in a paramagnetic field of a MACS separator. There are different
columns for different purposes and for different numbers of cells. Labeled cells (the positive
fraction) are retained inside the column due to the magnetic field, while the unlabeled ones
(the negative fraction) pass through the column. After loading, the sample column was rinsed
three times with a MACS buffer and the eluted fraction was collected. After removal of the
column from the magnetic field, the cells retained in the column can be rinsed with pressing
MACS buffer trough the column. This method enable us purification of cells by depleting all
the others cell types or by depleting a certain cell population.
MACS separation was used in order to purify dendritic cells (CD11c microbeads), to deplete
B and T cells (anti biotin microbeads after staining the samples with biotin labeled CD3 and
CD19 antibody) and for purification of CD4+CD62L+ T cells for the purpose of adoptive
T cell transfer described in section 4.2.1.7. Cells were isolated from either spleen or lymph
nodes. All procedures were performed according to the manufacturers instructions.
4.2.1.7 Adoptive T cell transfer for induction of chronic colitis
Chronic colitis was induced by transferring CD4+CD62L+ T cells from donor wild type
C57BL/6 mice to Rag1−/− recipient. The CD4+CD62L+ transfer model of chronic colitis
published by J. Munder in 2003 [198] resembles CD45RBℎ𝑖 model of colitis [199] with the
advantage that here is no need for a FACS sorter, but the cells can be prepared with a MACS
purification. CD4+CD62L+ double positive cells have been isolated from the spleen of wild
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type C57BL/6 animals. Single cell suspension from the spleen was performed as described in
section 4.2.1.1, only red blood cells were not lyzed. Than, the CD4+CD62L+ T cell isolation
kitII (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) was used for MACS purification.
In the first step of MACS purification, all non CD4+ T cells were depleted and in the second
step, CD4+ T cells were enriched for cells expressing CD62L. The purity was examined by
a FACS analysis and it ranged between 81 and 95 %. 3·105 isolated CD4+CD62L+ T cells
were intraperitoneally injected into a Rag1−/− recipient. The weight of injected mice was
measured regularly and the mice were opened and analysed on day 15 after T cell transfer.
4.2.1.8 Tissue homogenization for protein isolation
FastPrep System from MP Biomedicals (Solon-Ohio, Burlingame-California, USA) consist of
the whole repertoire of different Lysing matrixes and can be used to lyse, grind or homogenize
tough and resistant samples.
Before homogenization, tissue samples were snap-frozen in liquid nitrogen. For preparation
of whole gut protein homogenate samples, snap-frozen intestinal tissue samples, approxi-
mately 50 mg, were homogenized in 500 𝜇l PBS containing a cocktail of protease inhibitors
(cOmplete ULTRA Tablets, Roche, Sigma-Aldrich, Taufkirchen, Germany). For homogeniza-
tion, a tissue homogenizer (FastPrep-24, MP Biomedicals, Santa Ana, CA, USA) was used
(FastPrep speed: 6.0, FastPrep time: 40 sec). Homogenized samples were centrifugated at
9000 rpm for 5 min in order to pellet debris, supernatant was collected and spun again at
maximum speed. Remaining supernatant was stored at -20∘C. So prepared samples have
been used for measurements with Cytokine bead array (BD, Franklin Lakes, NJ, USA) and
for an IL-1 alpha enzyme linked immunosorbent assay (ELISA) Ready-SET-Go! kit or for an
IL-1 beta Pro-form ELISA Ready-SET-Go! kit (both purchased from Affymetrix eBioscience,
Santa Clara, CA, USA).
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4.2.1.9 Measuring of protein concentration
Whole gut protein homogenate samples were prepared as described in section 4.2.1.8. Pro-
tein concentration measurement was performed according to the manufacturers instructions
(Qubid Protein Assay Kit, Invitrogen, Eugene, Oregon, USA).
4.2.1.10 Cytometric Bead Array
Whole gut protein homogenate samples were prepared as described in section 4.2.1.8 and
protein concentration was measured as described in section 4.2.1.9.
BD Cytokine Bead Array mouse inflammation kit was used according to instructions pro-
vided by manufacturer. With this method we can measure up to six different cytokines in
each sample (IL-6, IL-10, MCP-1, IFN-g, TNF-a, and IL-12p70). Samples were diluted 1:1
with an Assay diluent and later acquired on a FACSCantoII. Results were analyzed using a
FCAP Array Software (Soft Flow Inc.). Cytokine levels were normalized on the total pro-
tein level present in each sample, which were measured by a Qubit fluorometer (Invitrogen,
Carlsbad, CA, USA).
4.2.1.11 Murine GM-CSF bone marrow culture
Animals were euthanized as described in section 4.2.1.1 disinfected with 70 % ethanol and cut
open. GM-CSF bone marrow dendritic cell culture was established in sterile conditions under
a laminar airflow cabinet (Heraeus, Hanau, Germany), like it was published by K. Inaba in
1992 [218]. Cells were plated in 100 mm petridishes in GM-CSF medium at a concentration
of 1·106 cells/ml. Cells were split on concentration 5·106 cells per plate on day 3 and 7 and
harvested on day 9 for the purpose of an IL-1 alpha and an IL-1 beta Pro-form ELISA.
4.2.1.12 ELISA for IL-1 alpha and IL-1 beta Pro-form
Whole gut protein homogenate samples were prepared as described in section 4.2.1.8 and
protein concentration was measured as described in section 4.2.1.9. Samples were diluted
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1:10 with an ELISA ELISPOT diluent and measured with an IL-1 alpha ELISA Ready-
SET-Go! kit or with an IL-1 beta Pro-form ELISA Ready-SET-Go! kit (both purchased
from Affymetrix eBioscience, Santa Clara, CA, USA) according to instructions provided by
manufacturer.
An IL-1 alpha ELISA Ready-SET-Go! kit and an IL-1 beta Pro-form ELISA Ready-SET-
Go! kit have also been used for measuring the interleukin level in lipopolysaccharide (LPS)
stimulated bone marrow derived dendritic cells (BMDCs) prepared as described in section
4.2.1.11. The BMDCs cells were harvested on day 9 and plated into a 96 well plate in
concentration 1·105 cells per well. Cells were stimulated for three hours at 37∘C with a
50 ng/ml LPS or they were left unstimulated. After incubation cells were centrifuged at
1500 rpm for 5 min and supernatant has been discharged. The 96 well plate was cooled to
-80∘C and thawed three times. Than centrifuged once more at 1500 rpm for 5 min and the
supernatant was transferred to a new 96 well plate and stored at -20∘C till further usage.
This samples have been diluted 1:3 with an ELISA ELISPOT diluent and have been used
for measuring of an IL-1 alpha and an IL1 beta Pro-form as described in the text above to
obtain whole gut protein homogenate samples.
4.2.1.13 Fecal protein extraction
Fecal samples were prepared according to protocol for fecal immunoglobulin extraction as
published previously [219] and adjusted for smaller amount of starting material.
4.2.1.14 Lipocalin-2 ELISA
Fecal samples were prepared as described in section 4.2.1.13 and diluted 1:600 with the Cal-
ibrator Diluent RD5-24 (1X). Lipocalin-2 was measured according to manufacture protocol
using a Quantikine ELISA kit for mouse Lipocalin-2/NGAL (R&D Systems Europe, Abing-
don, UK).
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4.2.1.15 CD40 injection
To evaluate the influence of CD40 signal on DCs animals were intraperitoneal (IP) injected
with 200 𝜇g of anti-CD40 antibody clone FGK4.5/FGK45 as described previously [142].
4.2.2 Molecular biology
4.2.2.1 Agarose gel electrophoresis
To visualize and separate deoxyribonucleic acid (DNA) fragments according to size, samples
were applied to an agarose gel. The gel consisted of 1 - 2 % agarose disolved in a TAE
buffer with addition of an ethidium bromide (0.5 𝜇g/mL) for later DNA visualization under
ultraviolet (UV) light. Separation of fragments on the gel was achieved with a constant
voltage (80 V) applied to an ectrophoresis chamber containing a conductive buffer (TAE). To
estimate the size of the fragments, either a 100 bp or a 1 kb ladder was used (New England
Biolabs, Ipswich, MA, USA). The polymerase chain reaction (PCR) fragments either already
contained the loading buffer or this buffer (10 % glycerol, xylene cyanol FF) was added before
applying the sample to the gel. The DNA samples were visualized by examination under UV
light (312 nm, Intas, Goettingen, Germany).
4.2.2.2 Isolation of genomic DNA and RNA
In order to isolate genomic DNA for genotyping, 2 - 5 mm of mouse tail tip was cut and
put into a 50 𝜇l digestiom mix consisting of Gitocher buffer, Triton, 2-mercaptoethanol and
Proteinase K. This mixture was incubated at 55∘C for 6 h, followed by a 5 min incubation at
95∘C for Proteinase K inactivation.
The isolation of nucleic acids for other purposes, where better DNA quality is needed (SNP
genotyping), was performed with a DNeasy Blood & Tissue Kit (Quiagen, Venlo, Netherlands)
according to instructions provided by manufacturer.
For ribonucleic acid (RNA) isolation, trizol RNA isolation protocol was used. Samples were
resuspended in 1 ml of trizol and snap-freezed with liquid nitrogen. For RNA preparation
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samples were melted and mixed with 300 µl of chloroform, centrifuged at full speed, the
aqueous phase was then again mixed with two volumes of chlorophorm and separated from
the non-aqueous phase after step of centrifugation. The aqueous phase was then transferred
to a fresh tube, mixed with one volume of 2-propanol and 1 µl of GlycoBlue (Ambion, Austin,
TX, USA) and incubated for 2 h, or overnight, at -20∘C. Precipitated RNA was spun down,
the pellet was washed with 70 % ethanol and resuspended in H2O. So prepared RNA have been
used for complementary DNA (cDNA) preparation with a QuantiTec Reverse Transcription
Kit (Qiagen, Venlo, Netherlands) according to instructions provided by manufacturer.
4.2.2.3 Polymerase chain reaction (PCR)
PCR is technique which enables amplification of a single, or multiple copies of DNA, in a
process where sequence specific primers, which flank the region of interest, amplify a focused
segment of DNA trough a thermal cycling in the presence of an enzyme DNA polymerase.
4.2.2.4 Quantitative PCR
Real time quantitative PCR (qPCR), is a technique based on traditional PCR reaction with
a few advantages: it combines nucleic acid amplification and detection in one step, smaller
amounts of starting material can be used and the product can be quantified based on fluores-
cent detection. Amplified DNA is fluorescently labelled and the amount of the fluorescence
released during DNA amplification is directly proportional to the amount of amplified DNA.
This enables measuring of fluorescence during the 30 to 45 cycles of a PCR process. The
cycle in which fluorescence can be detected is termed the quantitation cycle (Cq) and is the
basic result of the qPCR: lower Cq values mean higher initial copy numbers of the target.
There are two different methods to detect the amount of PCR product: SYBR green is a
fluorescent dye that interpolates with any double stranded DNA, whereas TaqMan probes
bind to a specific sequences.
In this thesis qPCR results were obtained with the TaqMan system and performed with the
LightCycler TaqMan Master Kit and the Universal ProbeLibrary Set mouse (both purchased
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from Roche Diagnostics Deutschland, Mannheim, Germany) according to the manufacturer
instructions on a LightCycler 480 System (Roche Diagnostics Deutschland, Mannheim, Ger-
many). Primers and probes used in this thesis are listed in the table of materials in section
4.1.6. Expression levels were normalized to the HPRT house-keeping gene and relative quan-
tification were calculated using the Delta-Delta Ct method [220].
4.2.2.5 SNP genotyping
High-quality SNP genotyping for the F2 DC-LMP1/CD40 genetically heterogenous mouse
strain was performed. DNA was prepared according to instructions provided by the manufac-
turer using a DNeasy Blood & Tissue Kit (Qiagen, Venlo, Netherlands). Samples were sent
to Illumina (San Diego, CA, USA) for genotyping service using the Mouse Linkage LD chip.
Ilumina Mouse LD Linkage Panel has 377 SNP loci chosen to maximize genetic information
across the top ten inbred strains routinely used for mouse crosses. This panel was designed to
include approximately four SNPs per each 27 Mb interval across the entire mouse genome. It
provides approximately 175 - 200 informative markers per cross and covers the entire mouse
genome.
Resulting SNPs in genes were identified with the help of the Mouse Linkage LD chip and
have been validated with the multiplication of the SNP region with locus specific primers.
Amplified genomic sequences were sequenced by MWG-Biotech AG (Ebersbach, Germany).
4.2.2.6 Statistics
For statistical analysis, PRISM software (GraphPad software, La Jolla, CA, USA) was used.
Bar graphs represent mean ± standard error of mean (SEM) and P-values were calculated
with a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P < 0.001.
5 Results
5.1 Phenotypic analysis of DC-LMP1/CD40 animals on
different genetic backgrounds
In order to study CD40 signaling without systemic effect of anti-CD40 antibody injection,
our group generated a mouse model where only DCs receive constant CD40 signaling [208].
As described in section 3.6.3, transgenic mice with constant CD40 signaling, here called DC-
LMP1/CD40 mice, on C57BL/6 genetic background develop B and T cell dependent fatal
colitis.
5.1.1 Exclusively C57BL/6 DC-LMP1/CD40 mice developed
spontaneous colitis
We observed that colitis development in DC-LMP1/CD40 mouse model depended on the
background of the animal. Only DC-LMP1/CD40 animals on C57BL/6 genetic background
developed colitis, while mice on BALB/c or F1 (mixed between C57BL/6 and BALB/c)
genetic backgrounds did not show any visible signs of disease. Histopathologic examination
showed a colitis-like phenotype in the lamina propria of C57BL/6 DC-LMP1/CD40 animals,
while no noticeable pathological changes were found in the spleen or any other organs (data not
shown). Histopathological analysis for C57BL/6 DC-LMP1/CD40 mice showed a thickening
of colon mucosa, extensive lamina propria infiltration of mixed inflammatory mononuclear
cells (macrophages, lymphocytes and plasma cells), as well as a loss of crypts, focal cryptitis,
ulceration and reduction of goblet cells (Fig.5.1 A). In contrast, F1 DC-LMP1/CD40 animals
showed only slight histopathologic changes compared to their background control littermates,
while BALB/c transgenic animals showed no changes compared to BALB/c wild type (wt)
animals (Fig.5.1 A).
Colitis was in C57BL/6 DC-LMP1/CD40 animals also visible on a macroscopic level by
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colon shortening and thickening (Fig.5.1 C). In contrast, the colons of F1 DC-LMP1/CD40
and BALB/c DC-LMP1/CD40 did not show any visible inflammation or shortening (Fig.5.1
B).
Fecal lipocalin-2 was published to be a good non-invasive inflammatory marker [221]. Mea-
surement of lipocalin-2 in DC-LMP1/CD40 animals showed high levels only in C57BL/6
DC-LMP1/CD40 animals, while in their control littermates and in transgenic animals on
BALB/c genetic backgrounds, no increase in fecal lipocalin-2 could be observed (Fig.5.1 C).
F1 DC-LMP1/CD40 animals had slightly increased levels of fecal lipocalin-2, when compared
to their control littermates. However, levels of fecal lipocalin-2 measured in F1 transgenic
animals were way below the levels which could be measured in C57BL/6 transgenic animals
(Fig.5.1 C).
How constant CD40 triggering in DCs affected the levels of pro-inflammatory cytokines
was further analyzed with Cytometric Bead Array (CBA). Cytokines were measured in
whole gut homogenate of C57BL/6 DC-LMP1/CD40 and F1 DC-LMP1/CD40 animals with
suitable controls. A significant increase of pro-inflammatory cytokines monocyte chemoat-
tractant protein-1 (MCP1), TNF-𝛼, IFN-𝛾 and IL-6 was found, while anti-inflammatory IL-10
was significantly reduced in C57BL/6 DC-LMP1/CD40 animals compared to their littermate
controls (Fig.5.2 B, upper panel). However, no change in any of the six analyzed cytokines
could be observed for F1 DC-LMP1/CD40 animals (Fig.5.2).
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Figure 5.1: DC-LMP1/CD40 animals on C57BL/6 genetic background developed
strong intestinal inflammation with colitis. A) DC-LMP1/CD40 mice on C57BL/6 back-
ground displayed severe colitis with a thickening of the colon mucosa, extensive proprial infil-
tration of mixed inflammatory mononuclear cells, loss of crypts and reduction of goblet cells.
DC-LMP1/CD40 mice on F1 background showed only slight changes in comparison to con-
trols (Ctr), while transgenic mice on BALB/c background showed no changes in comparison to
BALB/c wt mice. Paraffin sections, HE-staining. Bars = 100 𝜇m. B) Macroscopic pictures
of colons from control and DC-LMP1/CD40 animals on different genetic backgrounds. Bars =
1 cm. C) Levels of fecal lipocalin-2 as measured by ELISA in 8-10 week old DC-LMP1/CD40
animals on different genetic backgrounds. Shown are pooled statistics from 3 experiments (n =
6-10). All bar graphs represent mean ± standard error of mean (SEM) where significance was
analyzed using a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P < 0.001.
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Figure 5.2: Increased proinflammatory cytokines in the intestine of C57BL/6 DC-
LMP1/CD40 animals. Levels of pro-inflammatory cytokines were measured in colon ho-
mogenates from 8-12 week old DC-LMP1/CD40 mice on C57BL/6 and on a mixed F1 genetic
background. Cytokine concentrations were measured with a Cytometric Bead Array (CBA) kit
and normalized to the total protein content for each sample. Shown are pooled statistics from
2 experiments (n = 7). All bar graphs represent mean ± standard error of mean (SEM) where
significance was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P <
0.001.
5.1.2 Reduction of tolerogenic CD103+ DCs was independent of the
genetic background
From the previous publication it was known that CD103+ DC subsets have been strongly
reduced in DC-LMP1/CD40 animals on C57BL/6 genetic background [208]. Therefore, we
next analyzed the numbers and frequencies of these DCs also in the other backgrounds.
Analysis of colonic lamina propria (LP) showed strong reduction in the frequencies of
CD103+CD11b− and CD103+CD11b+ tolerogenic DCs in all three transgenic mouse strains
(Fig.5.3 A). On the other hand a higher frequencies of CD103−CD11b+ DCs were found in
transgenic animals compared to their control littermates. Analysis of DC subsets in mLNs
showed similar effect of LMP1/CD40 on CD103+ DCs, which were also strongly reduced in
all transgenic animals (Fig.5.3 B).
To find out if the differential effect of the CD40-signaling on CD103+ and CD103− DCs was
due to differential transgene expression, CD103+ and CD103− DCs were sorted from LP of
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C57BL/6 DC-LMP1/CD40 animals and qPCR with primers specific for the LMP1/CD40 gene
construct was performed. Surprisingly, we found that the expression of LMP1/CD40 gene
was significantly higher in CD103− DCs when compared to CD103+ counterparts (Fig.5.4).
Despite the fact that CD103− DCs expressed relatively higher levels of the LMP1/CD40
transgene as compared to CD103+ DCs they were not affected by CD40 signaling in the same
way like the others DC subsets.
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Figure 5.3: CD103+ DCs were strongly reduced in LP and mLN of DC-LMP1/CD40
animals. DC subsets in the LP (A) or mLN (B) were analyzed in DC-LMP1/CD40
animals on different genetic backgrounds. A) LP cells were gated on single cells, live,
CD45+MHCII+CD11c+CD64− cells from control (Ctr) or DC-LMP1/CD40 mice on different
genetic backgrounds. Representative FACS-plots are shown, numbers and bar graphs indicate
the frequency of DC subsets. Shown are pooled statistics from 5 experiments for C57BL/6 DC-
LMP1/CD40 animals (n = 14-18), from 6 experiments for F1 DC-LMP1/CD40 animals (n =
19-20) and from 2 experiments for BALB/c DC-LMP1/CD40 animals (n = 6-7). B) mLNs cells
were gated on single cells, live, MHCII+CD11c+ cells from control or DC-LMP1/CD40 mice on
different genetic backgrounds. Representative FACS-plots are shown, numbers and bar graphs
indicate frequency of DC subsets. Shown are pooled statistics from 4 experiments for C57BL/6
DC-LMP1/CD40 animals (n = 12-14), from 5 experiments for F1 DC-LMP1/CD40 animals (n
= 18) and from 2 experiments for BALB/c DC-LMP1/CD40 animals (n = 6-7). All bar graphs
represent mean ± SEM where significance was analyzed using a students t-test, with *: P <
0.05, **: P < 0.01 and ***: P < 0.001.
5.1 Phenotypic analysis of DC-LMP1/CD40 animals on different genetic backgrounds 55
re
la
tiv
e 
tra
ns
ge
ne
ex
pr
es
si
on
LMP1/CD40
CD103- LP DCs
CD103+ LP DCs0
1
2
3 *
Figure 5.4: CD103+ and CD103− DCs expressed LMP1/CD40 transgene. CD103+
and CD103− DCs were sorted from LP (single, live, CD45+MHCII+CD11c+CD64−) of C57BL/6
control and C57BL/6 DC-LMP1/CD40 animals. Trizol RNA isolation protocol was used for
RNA isolation, from which cDNA was prepared. Samples were analyzed by qPCR with primers
specific for LMP1/CD40 construct. Data was normalized on HPRT expression. Shown is pooled
data from 2 experiments (n = 4). All bar graphs represent mean ± SEM where significance was
analyzed using a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P < 0.001.
5.1.2.1 CD103+ DCs were stronger reduced in DC-LMP1/CD40 animals on
C57BL/6 than on other backgrounds
As shown in Fig.5.3 A and B, CD103+ DCs were strongly reduced in LP and mLNs of DC-
LMP1/CD40 transgenic animals of all genetic backgrounds. However, they were more reduced
in C57BL/6 DC-LMP1/CD40 animals as compared to BALB/c and F1 DC-LMP1/CD40 ani-
mals. In order to compare DC subpopulations in DC-LMP1/CD40 animals on different genetic
backgrounds, we calculated the percentage of each DC subset in transgenic mice, where cor-
responding background wt controls represent 100 % for each respective analyzed DC subset.
When we analyzed results in this way, we found that the tolerogenic CD103+CD11b− DC sub-
set showed the strongest reduction to approximately 10 % of wild type in LP (Fig.5.5 A) and
mLNs (Fig.5.5 B) of C57BL/6 DC-LMP1/CD40 animals. F1 transgenic animals showed an
intermediate nearly to approximately 40 % of wild type levels reduction of CD103+CD11b−
DC, while frequency of this DC subpopulation was reduced to only 60 % of wild type on
BALB/c background. On the other hand CD103+CD11b+ DCs were similarly reduced in
LP of all transgenic animals, while they were differentialy affected in mLNs, where C57BL/6
transgenic animals had the lowest frequency, while BALB/c DC-LMP1/CD40 animals had
the highest frequencies of this second tolerogenic DC-subpopulation. Additionally, a relative
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increase of CD103−CD11b+ DCs was observed in all trangenic animals compared to wt ani-
mals, however, the strongest increase could be seen in LP (Fig.5.5 A) and mLNs (Fig.5.5 B)
of C57BL/6 DC-LMP1/CD40 animals.
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Figure 5.5: Relative changes of DC subpopulations as compared to wild type mice
in different genetic backgrounds. DC subsets in the LP (A) or mLN (B) were analyzed
as described in figure 5.3. The frequencies for each DC subset in DC-LMP1/CD40 animals on
different genetic backgrounds are shown as relative percentage as compared to corresponding
background control, which has been set to 100 % (red line). A) Relative frequencies for LP
samples shown in figure 5.3 A. B) Relative frequencies for mLNs samples shown in figure 5.3 B.
All bar graphs represent mean ± SEM where significance was analyzed using a students t-test,
with *: P < 0.05, **: P < 0.01 and ***: P < 0.001.
CD40 signaling has been previously connected with an improvement of antigen presentation
capacity and maturation of DCs [129, 130, 131]. Therefore, surface markers of DCs from
DC-LMP1/CD40 animals were analyzed and compared in C57BL/6 DC-LMP1/CD40 and
F1 DC-LMP1/CD40 animals. The only strong difference which could be observed between
these two transgenic mouse strains was that all DC subsets in C57BL/6 DC-LMP1/CD40
animals consistently showed lower surface expression of MHC class II molecule compared to
background control wt animals. This effect could be observed in LP (Fig.5.6 A) and mLNs
(Fig.5.6 B). However, significant differential expression of CD86 co-stimulatory molecule in
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LP of both transgenic strains could not be observed (Fig.5.6 A), while down-regulation of
CD86 on mLNs CD103+CD11b− DCs in transgenic animals on both backgrounds was detected
(Fig.5.6 B). In contrast, CD86 was upregulated on CD103+CD11b− DCs in both transgenic
strains and on CD103+CD11b+ DCs only in F1 DC-LMP1/CD40 animals (Fig.5.6 B). Also
CD80 expression on DC subsets was analyzed and a weak up-regulation in LP DCs of both
transgenic strains could be detected (Fig.5.6 A), while up-regulation was even stronger on
mLN DCs (Fig.5.6 B).
In order to compare activation profiles of DCs in transgenic animals with different ge-
netic backgrounds, the percentage of mean fluorescence intensity (MFI) from co-stimulatory
molecules on each DC subset was calculated. The MFI of corresponding wt mice in the
same genetic background represented 100 % for analyzed co-stimulatory molecules on each
specific DC subset. When analyzed in such a comparative relative way, DCs from C57BL/6
DC-LMP1/CD40 animals showed lower expression of MHC class II molecules on LP DCs,
higher expression of CD80 and lower expression of CD86 in mLN DCs as compared to F1
DC-LMP1/CD40 animals (Fig.5.7 A and B).
5.1 Phenotypic analysis of DC-LMP1/CD40 animals on different genetic backgrounds 58
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
CD103+CD11b- CD103+CD11b+ CD103-CD11b+
C
D
86
C
D
80
M
H
C
II
Ctr
DC-LMP1/CD40
CD103+CD11b- CD103+CD11b+
0 102 103 104 105
CD103+CD11b- CD103+CD11b+
C
D
86
C
D
80
M
H
C
II
CD103+CD11b- CD103+CD11b+ CD103-
F1C57BL/6
0
20
40
60
80
100
*
2846±173
5208±769
0
20
40
60
80
100 1858±136
2842±388
***
2477±389
6967±856
0
20
40
60
80
100 1802±138
2460±297
**
2363±163
4609±687
2334±175
3993±587
0 102 103 104 105
0
20
40
60
80
100 1717±132
1861±184
1496±184
1712±198
0 102 103 104 105
1330±135
1210±127
0 102 103 104 105
0
20
40
60
80
100
1578±109
1711±169
0 102 103 104 105
1242±87
1620±279
0 102 103 104 105
1354±108
1509±145
0
20
40
60
80
100
** ******
1011±154
2553±181
***
944±78
2236±95
603±49
632±39
971±105
2495±248
***
848±54
1189±61
CD103-CD11b+
CD103-
*** *** *** *** ***
62865±4123
11479±884
82182±5344
13726±1559
79237±5476
14957±1480
63821±6457
40841±5930
78824±5686
47010±5993
85590±6166
58704±7760
* *
837±48
1274±87
0 102 103 104 1050 102 103 104 1050 102 103 104 105
0
20
40
60
80
100
0 102 103 104 105 0 102 103 104 105
** * ** *
1305±115
965±54
1502±142
1533±88
685±54
846±30
1289±142
2164±176
550±62
824±72
0 102 103 104 105
0
20
40
60
80
100
**
1133±89
833±52
***
33892±2122
24562±1148
*
37601±3509
27768±1269
25025±1486
26391±1186
38395±4104
28173±2122
40168±4257
29747±2054
26630±2647
24725±1436
* *
F1C57BL/6
Ctr
DC-LMP1/CD40
A   lamina propria
B    mLN
Figure 5.6: DC-LMP1/CD40 DCs from mLN and LP were more activated than
their control counterparts. DC subsets of the LP (A) or mLN (B) were analyzed for the
expression of different activation markers. Shown are representative histograms of wt controls
(filled grey) and DC-LMP1/CD40 (black line). Numbers represent MFI ± standard error of
mean (SEM). A) Shown are pooled statistics from 5 experiments for C57BL/6 DC-LMP1/CD40
animals (n = 8-18) and from 6 experiments for F1 DC-LMP1/CD40 animals (n = 12-20). B)
Shown are pooled statistics from 4 experiments for C57BL/6 DC-LMP1/CD40 animals (n =
6-14) and from 5 experiments for F1 DC/LMP1/CD40 animals (n = 10-18). The significance
was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P < 0.001.
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Figure 5.7: Relative changes of surface markers of DC subpopulations as compared
to wild type mice in different genetic backgrounds. DC subsets in the LP (A) or mLN
(B) were analyzed as described in figure 5.6. MFI values for activation markers of each DC
subset in different DC-LMP1/CD40 animals are shown relative to corresponding background
control which was set to 100 % (red line). A) Relative calculations for lamina propria samples
shown in figure 5.6 A. B) Relative calculations were performed for mLNs samples shown in figure
5.6 B. The significance was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01
and ***: P < 0.001.
5.1.3 DC-LMP1/CD40 mice lack iTreg cells
Since DC-LMP1/CD40 animals had a strongly reduced frequency of intestinal CD103+ DCs,
which were previously shown to be crucial for iTreg cell induction [107, 108], we next inves-
tigated the intestinal Treg cell compartment. When comparing total FoxP3+ Treg cells in
different organs no differences in Treg frequencies between transgenic and wild type animals
could be found [208]. However, when peripherally induced iTreg (Helios−) and thymus in-
duced nTreg cells (Helios+) were analyzed separately, significantly fewer induced iTreg cells
was found (Fig.5.8 A). In LP of C57BL/6 DC-LMP1/CD40 animals 13 % of Tregs were
iTregs, as compared to 80 % of iTregs in wt animals (Fig.5.8 A). Also in F1 DC-LMP1/CD40
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and BALB/c DC-LMP1/CD40 animals a reduction in the iTreg cell compartment could be
observed. However, in F1 transgenic animals around 40 % iTregs (F1 controls 80 %) could be
detected, while in BALB/c DC-LMP1/CD40 animals 38 % of Tregs were iTregs, as compared
to 54 % of iTregs in wt animals (Fig.5.8 A). In LP of all transgenic animals high amounts of
nTreg cells could be found which apparently filled the Treg cell compartment.
The separation between iTreg and nTreg cells in mLNs according to Helios expression is
not as clear as in LP, but when analyzed the results have shown the same tendency as in LP.
However, in mLNs iTreg cells in BALB/c DC-LMP1/CD40 animals were not significantly
reduced when compared to wt animals (Fig.5.8 B).
In the next step, the relative amounts of Treg cells according to background control were
analyzed analogous to the analysis performed for DC subpopulations. Using this analysis,
the amount of iTreg cells between DC-LMP1/CD40 animals of different genetic origins could
be compared. The percentage of each Treg subset in transgenic animals, where suitable
background wt control represented 100 % for analyzed DC subset, was calculated. This
analysis showed that the reduction of iTregs was most prominent in transgenic animals on
C57BL/6 background. F1 DC-LMP1/CD40 animals had intermediate levels of iTregs, while
transgenic BALB/c animals showed only a very mild reduction of iTregs (Fig.5.9).
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Figure 5.8: iTreg induction was severely impaired in DC-LMP1/CD40 animals.
Single cell suspensions of LP (A) and mLN (B) were analyzed for Treg cells. A) Shown
are representative FACS-plots of FoxP3+ Tregs found in the LP pre-gated on single, live,
CD45+CD3+CD4+CD25+FoxP3+ and in the next step subdivided into nTregs and iTregs us-
ing Helios as a marker for thymic derived Tregs. Numbers on FACS-plots and bar graphs on
their right side indicate the frequency of Treg cell subsets, separately for each analyzed genetic
background. Shown are pooled statistics from 7 experiments for C57BL/6 DC-LMP1/CD40
animals (n = 23-26), from 6 experiments for F1 DC-LMP1/CD40 animals (n = 21) and from 2
experiments for BALB/c DC-LMP1/CD40 animals (n = 7). B) Shown are representative FACS-
plots of FoxP3+ Tregs found in the mLN pregated on single, live, CD3+CD4+CD25+FoxP3+
and in the next step subdivided into nTregs and iTregs using Helios. Numbers on FACS-plots
and bar graphs on their left side indicate the frequency of Treg cell subsets, separately for each
analyzed genetic background. Shown are pooled statistics from 4 experiments for C57BL/6
DC-LMP1/CD40 animals (n = 12), from 4 experiments for F1 DC-LMP1/CD40 animals (n =
16-18) and from 2 experiments for BALB/c DC-LMP1/CD40 animals (n = 5-6). All bar graphs
represent mean ± SEM where significance was analyzed using a students t-test, with *: P <
0.05, **: P < 0.01 and ***: P < 0.001. Ctr = control.
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Figure 5.9: Analyses of iTreg and nTreg frequencies relative to wt controls in the
corresponding genetic backgrounds. Treg cell subsets in the LP (A) or mLN (B) were
analyzed as described in figure 5.8 A and B. The frequencies for each Treg cell subset in DC-
LMP1/CD40 animals on different genetic backgrounds are shown as relative to corresponding
background control (red line represents average frequency of background control). A) Relative
calculations were performed for lamina propria samples shown in figure 5.8 A. B) Relative
calculations were performed for mLN samples shown in figure 5.8 B. All bar graphs represent
mean ± SEM where significance was analyzed using a students t-test, with *: P < 0.05, **: P
< 0.01 and ***: P < 0.001.
5.1.4 More CD103+ DCs resulted in more iTregs
Data of DCs and iTregs in DC-LMP1/CD40 animals on different genetic backgrounds sug-
gested that more CD103+ DCs resulted in more iTregs. Samples from the very same animals
were stained for DCs and iTreg cells and plotted on scatter plot, where DC subsets are shown
on the y-axis versus iTregs shown on the x-axis. As transgenic animals in different genetic
backgrounds were plotted into the same scatter plot, we calculated the percentage of the
analyzed DC or iTreg subset in relation to the corresponding wt controls in the very same
genetic background. A linear fit was applied to this data and the Pearson coefficient cal-
culated. A strong positive correlation between the presence of CD103+ subsets of DCs and
Helios− iTreg cells in LP (Fig.5.10 A) and in mLNs could be observed (Fig.5.10 B). The cor-
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relation was stronger for CD103+CD11b− than for CD103+CD11b+ DCs, while analysis of
the CD103−CD11b+ DCs gave us a negative correlation with iTregs for both analyzed organs
(Fig.5.10 A and B). The strength of the co-occurrence between DC subpopulations and iTregs
was represented with the Pearson Correlation coefficient (r), whose values can range between
-1 (the strongest negative correlation) and +1 (the strongest positive correlation). From the
scatter plot could therefore be visible that more CD103+ DCs could induce more iTreg cells,
where CD103+CD11b− DCs had better tolerogenic properties. On the other hand we could
show that higher percentage of CD103− DCs did not lead to higher percentage of iTregs.
Since C57BL/6 DC-LMP1/CD40 animals had the lowest percentage of CD103+ DCs, this
resulted in the lowest percentage of iTreg cells, while F1 and specially BALB/c transgenic
animals had more CD103+ DCs and consequently more iTreg cells.
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Figure 5.10: Positive correlation between tolerogenic CD103+ DCs and iTreg cells.
DC subsets and iTreg cells were analyzed for each mouse at the same time. DCs were prepared
and analyzed as described in figure 5.5 (A) for LP and (B) for mLN. iTregs (Helios−) cells were
prepared and analyzed as described in figure 5.9 (A) for LP and (B) for mLNs. Each symbol
on the scatter plot represents one mouse. Linearly fitted line was added on each scatter plot
to visualize the relationship between DC subpopulations and iTreg cells. The strength of co-
occurrence between DC subpopulation and iTregs is represented with the Pearson Correlation
coefficient (r), whose values range between -1 and +1. A) Data for LP was acquired and
pooled from 3 separate experiments for C57BL/6 DC-LMP1/CD40 animals (n = 10-12), from 4
experiments for F1 DC-LMP1/CD40 animals (n = 13-14) and from 2 experiments for BALB/c
DC-LMP1/CD40 animals (n = 6-7). B) Data for mLNs was acquired and pooled from 2 separate
experiments for C57BL/6 DC-LMP1/CD40 animals (n = 6-8), from 3 experiments for F1 DC-
LMP1/CD40 animals (n = 12) and from 2 experiments for BALB/c DC-LMP1/CD40 animals
(n = 5-6).
5.1.5 C57BL/6 DC-LMP1/CD40 mice showed a breakdown of
intestinal tolerance
We have previously shown [208] that colitis in C57BL/6 DC-LMP1/CD40 depended on B
and T cells, since mice on RAG−/− genetic background did not develop the disease (Fig.3.1
A). Therefore, we further characterized T cells and found a significantly increased amount
of IL-17+IFN-𝛾+ and IL-17−IFN-𝛾+ T cells in LP (Fig.5.11) as well as in mLNs and in the
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spleen (Fig.5.12 A and B) of C57BL/6 DC-LMP1/CD40 animals. In contrast to LP, in mLNs
and spleen of C57BL/6 DC-LMP1/CD40 animals also IL-17+IFN-𝛾− T cells were increased
(Fig.5.12 A and B). However, F1 DC-LMP1/CD40 animals showed a different distribution
of T cell subsets. There, a high amount of IL-17+IFN-𝛾− T cells could be shown in LP
(Fig.5.11) and a slightly higher, but also significant amount of these cells in the spleen (5.12
B). In contrast to C57BL/6 DC-LMP1/CD40 animals in mice of the F1 background LP IL-
17+IFN-𝛾+ T cells were only slightly increased, while IL-17−IFN-𝛾+ T cells were not increased
(Fig.5.11 and 5.12). Similar like in F1 transgenic animals also in BALB/c DC-LMP1/CD40
animals IFN-𝛾 expressing cells were not increased in any analyzed organ, while the same held
true for IL-17 expressing cells (Fig.5.11 and 5.12).
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Figure 5.11: Increased number of IFN-𝛾 and IL-17 producing T cells in the LP of
DC-LMP1/CD40 animals on C57BL/6 background. T cell functionality was analyzed by
stimulating single cell suspensions with PMA/Ionomycin for 4 h, subsequently cells were stained
intracelluarly for the production of IL-17 and IFN-𝛾. Shown are representative FACS-plots with
indicated frequencies for LP (gated on single, live, CD45+CD3+CD4+). Bar graphs represent the
pooled statistics from 4 experiments for C57BL/6 DC-LMP1/CD40 animals (n = 11-12), from 6
experiments for F1 DC-LMP1/CD40 animals (n = 17-18) and from 2 experiments for BALB/c
DC-LMP1/CD40 animals (n = 7). All bar graphs represent mean ± SEM where significance
was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P < 0.001. Ctr
= control.
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Figure 5.12: Effector T cell subsets in mLN and spleen. T cell functionality was analyzed
by stimulating single cell suspensions with PMA/Ionomycin for 4 h, subsequently cells were
stained intracelluarly for the production of IL-17 and IFN-𝛾. Shown are representative FACS-
plots with indicated frequencies for mLN (A) (gated on single, live, CD3+CD4+) and for the
spleen (B) (gated on single, live, CD3+CD4+). A) Bar graphs represent the pooled statistics
for frequencies of Th subpopulations from 4 experiments for C57BL/6 DC-LMP1/CD40 animals
(n = 10-12), from 4 experiments for F1 DC-LMP1/CD40 animals (n = 10-12) and from 2
experiments for BALB/c DC-LMP1/CD40 animals (n = 6-7). B) Bar graphs represent the
pooled statistics for frequencies of Th subpopulations from 4 experiments for C57BL/6 DC-
LMP1/CD40 animals (n = 12), from 5 experiments for F1 DC-LMP1/CD40 animals (n = 15)
and from 2 experiments for BALB/c DC-LMP1/CD40 animals (n = 6). All bar graphs represent
mean ± SEM where significance was analyzed using a students t-test, with *: P < 0.05, **: P
< 0.01 and ***: P < 0.001. Ctr = control.
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Similar to the relative calculations for DCs and Tregs shown above, the relative frequencies
of effector T cells subsets were calculated for each genetic background of DC-LMP1/CD40
animals separately in relation to their corresponding wild type counterparts. This kind of
analysis was performed in order to compare the frequencies of effector T cells between DC-
LMP1/CD40 animals of different genetic origins. When results were analyzed like this, we
found that C57BL/6 DC-LMP1/CD40 animals had the highest amount of LP IL-17−IFN-
𝛾+ T cells among all three DC-LMP1/CD40 strains (Fig.5.13 A). In contrast, F1 transgenic
animals had the highest relative frequency of IL-17+IFN-𝛾− T cells, while the effector T
cell compartment of transgenic BALB/c DC-LMP1/CD40 animals was not changed when
compared to their BALB/c wt controls (Fig.5.13 A). The situation in mLNs was slightly
different, since there C57BL/6 DC-LMP1/CD40 animals had the highest relative increase of
all effector T cell subsets (Fig.5.13 B). The same was true for the spleen (Fig.5.13 C).
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Figure 5.13: Comparative analysis of effector T cells in three different genetic back-
grounds. IL-17+IFN-𝛾−, IL-17+IFN-𝛾+ and IL-17−IFN-𝛾+ Th cell subsets in LP (A), mLN
(B) and spleen (C) were analyzed as described in figures 5.11 and 5.12. The frequencies for
each Th cell subset in DC-LMP1/CD40 animals on different genetic backgrounds are shown as
relative to suitable background control (red line represents average frequency of background con-
trol). A) Relative calculations were performed for lamina propria samples shown in figure 5.11.
B) Relative calculations were performed for mLN samples shown in figure 5.12 A. C) Relative
calculations were performed for spleen samples shown in figure 5.12 B. All bar graphs represent
mean ± SEM where significance was analyzed using a students t-test, with *: P < 0.05, **: P
< 0.01 and ***: P < 0.001.
5.1.5.1 Th17 cells in C57BL/6 DC-LMP1/CD40 animals showed a more pathogenic
phenotype
Th17 cells in the periphery are not a homogeneous population and can confer host protection
as well as autoimmune diseases [171, 172]. For their initial commitment to the Th17 lineage,
T cells need TGF-𝛽1 and IL-6 in order to differentiate into a more protective Th17 cell type
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[173, 175]. However, if they are exposed to IL-23, and according to some publications also IL-
1𝛽, they develop a more pathogenic phenotype, which among others includes T-bet expression
and IFN-𝛾 production [176, 163, 222]. Since Th17 cells show late developmental plasticity
and different degrees of pathogenicity and since we have shown that transgenic animals of
different strains differed in the structure of the Th17 repertoire, we performed additional
experiments in order to further identify the type of Th17 cells in the different mouse types.
First, T-bet expression in IL-17+IFN-𝛾−, IL-17+IFN-𝛾+ and IL-17−IFN-𝛾+ T cell subsets
was compared in C57BL/5 DC-LMP1/CD40 animals. This analysis showed that IL-17+IFN-
𝛾− cells expressed the lowest level, IL-17+IFN-𝛾+ intermediate level and IL-17−IFN-𝛾+ the
highest level of the transcription factor T-bet (Fig.5.14 A). It is known that IL-17 expression
of Th17 cells is transient in some inflammatory settings, which means that cells after IL-23
conversion can stop expressing IL-17 and only express IFN-𝛾. These cells were therefore
named ex-Th17 cells or Th1-like cells [177]. Therefore, this could mean that IL-17−IFN-𝛾+ T
cells identified in C57BL/6 DC-LMP1/CD40 animals were actually ex-Th17 cells which have
lost IL-17 expression. We could show that IL-17+IFN-𝛾− T cells from C57BL/6 transgenic
animals had significantly higher T-bet levels than their wt controls, suggesting their potential
for further differentiation towards a more Th1-like phenotype (Fig.5.14 B). In contrast, this
was not found for F1 DC-LMP1/CD40 animals where no elevated levels of T-bet were observed
(Fig.5.14 B). The latter suggested that IL-17+IFN-𝛾− T cells in F1 DC-LMP1/CD40 animals
would not develop further into pathogenic ex-Th17 cells or Th1-like cells. Analysis of T-bet
expression in T cells from BALB/c DC-LMP1/CD40 animals was unfortunately not possible
since we did not have enough animals.
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Figure 5.14: IL-17+IFN-𝛾− cells from C57BL/6 DC-LMP1/CD40 animals showed a
more pathogenic phenotype than those from F1 DC-LMP1/CD40 animals. A) IL-
17+IFN-𝛾−, IL-17+IFN-𝛾+ and IL-17−IFN-𝛾+ T cells from C57BL/5 DC-LMP1/CD40 animals
were analyzed for T-bet expression. The bar graph represents the pooled statistics for MFI
of T-bet expression from 2 experiments (n = 6). B) Shown are representative histograms of
controls (filled grey) and DC-LMP1/CD40 (black line) for T-bet expression in IL-17+IFN-𝛾− T
cells from C57BL/6 and from F1 mixed background transgenic animals. The numbers on the
histograms represent mean ± SEM, which is additionally displayed on the bar graph on the right
side. For statistics, data from 2 experiments was pooled (n = 5-6). Bar graph represents mean
± SEM where significance was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01
and ***: P < 0.001.
Taken together the extensive phenotypic analysis of DC-LMP1/CD40 mice on different
genetic backgrounds showed that only transgenic animals on C57BL/6 genetic background
developed colitis-like phenotype, showed high levels of inflammatory marker lipocalin-2 in
feces and increased levels of proinflammatory cytokines in the intestine. However, all DC-
LMP1/CD40 animals showed strong reduction of tolerogenic CD103+ DC subsets, which was
the strongest for C57BL/6 transgenic animals. Additionally, all DC-LMP1/CD40 animals
had reduced frequencies of Helios− iTregs when compared to wt animals. However, mice on
C57BL/6 genetic background were the most affected, F1 animals showed the intermediate
reduction, while iTregs in BALB/c transgenic animals were only slightly reduced. We could
show the existence of positive correlation between CD103+ DC subsets and iTreg cells where
CD103+CD11b− DC subset had stronger tolerogenic properties. The analysis of effector T
cell subsets in DC-LMP1/CD40 animals has shown the strong expansion of pathogenic IL-
17+IFN-𝛾+ T cells only in transgenic animals of C57BL/6 origin, while F1 transgenic animals
had more lamina propria IL-17+IFN-𝛾− T cells and BALB/c DC-LMP1/CD40 animals did
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not have elevated levels of effector T cells when compared to BALB/c wt animals.
5.2 CD40 signaling induced migration of intestinal DCs
from LP to mLNs
As described in section 3.4, the alternative way of studying CD40 signaling in DCs is with
a simple intra-peritoneal injection of anti-CD40 mAb into the mouse. This is not an ideal
method due to the systemic effect of the anti-CD40 antibody on all cells expressing the CD40
molecule, but it offers some advantages over the constitutive DC-LMP1/CD40 model. The
biggest disadvantage of the DC-LMP1/CD40 mouse model is that it is always on, meaning
that DCs receive a CD40 signal from the moment when they start expressing CD11c. There-
fore, it is hard to identify which of the observed effects is a primary effect due to the triggering
of the CD40 pathway in DC and which are actually secondary effects.
We published that CD40 signaling induced migration of intestinal DCs from LP to mLNs
[208]. To study the influence of CD40 signaling on DCs, anti-CD40 antibody was IP injected in
wt C57BL/6 mice and LP and mLNs DC subsets were analyzed 24 h post treatment. A strong
reduction of CD103+CD11b− and CD103+CD11b+ DC subsets was found in LP (Fig.5.15 A
(black)), while they were strongly increased in mLNs of treated animals (Fig.5.15 A (red)).
In combination with a measured increase of CCR7 levels, which is a chemokine receptor
needed for the migration of cells via the afferent lymph towards mLNs [55], especially on LP
CD103+ DCs (Fig.5.15 B), this result suggested that CD40 stimulus induced an increased
exit of CD103+ DCs from lamina propria and their further migration towards mLNs. To
test if DCs really migrated due to the triggering of the CD40 pathway in them, we injected
anti-CD40 in mice which lack the CD40 molecule specifically on CD11c+ DCs. In these mice
the treatment did not induce the migration of CD103+ DCs [208], therefore we could argue
that the migration of DCs was a direct effect of CD40 crosslinking.
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Figure 5.15: Injection of anti-CD40 antibody in wt mouse induced migration of
CD103+ DCs from LP to mLNs. A) A percentage of DCs for each DC subset and absolute
numbers of cells per DC subset in lamina propria (black) and mLNs (red) are shown. Shown are
pooled statistics from 4 separate experiments (n = 11-14). Wild type C57BL/6 animals were IP
injected with an anti-CD40 antibody and analyzed 24h post injection. B) CCR7 expression was
analyzed in different subsets of LP DCs from wt C57BL/6 animals injected with the anti-CD40
antibody (IP injection, 24 hours) or untreated controls. Shown are representative histograms of
isotype control staining (filled grey), controls (grey line) and anti-CD40 injected animals (black
line) for CCR7 staining in different subsets of LP DCs. Numbers on histograms represent MFI ±
SEM from 2 pooled experiments (n = 6). The significance was analyzed using a students t-test,
with *: P < 0.05, **: P < 0.01 and ***: P < 0.001. Ctr = control; n.s. = not significant. Black
stars indicate significance for lamina propria cell subsets, while red stars indicate significance for
mLN cell subsets.
5.2.1 Influence of anti-CD40 injection on DCs in C57BL/6 wt and
BALB/c wt mice
Since higher frequencies of CD103+ DCs were observed in F1 and BALB/c DC-LMP1/CD40
animals than in transgenic animals on a C57BL/6 genetic background (Fig.5.5), we tested
5.2 CD40 signaling induced migration of intestinal DCs from LP to mLNs 73
if differential CD40 signaling between C57BL/6 and BALB/c mice could be the reason for
the observed differences. An anti-CD40 mAb was IP injected in each mouse strain and after
24 h DC subsets of LP and mLNs were analyzed. Anti-CD40 treated animals were compared
with uninjected controls of the same strain. DCs of both mouse strains responded similarly
to the activation of their CD40 pathway. A reduction of CD103+ DCs could be observed
in LP, while their frequencies increased in mLNs (Fig.5.16 A and B). However, while many
CD103+ DCs migrated from LP to mLNs in BALB/c, this depletion was not as complete as
compared to C57BL/6 animals. CCR7 chemokine receptor up-regulation was also found to
be stronger expressed on DCs from C57BL/6 animals as compared to these from BALB/c
animals, eventually explaining the less efficient migration in the latter (Fig.5.16 C).
After it was observed that BALB/c wt animals had more CD103+CD11b− DCs than
C57BL/6 wt animals, it was tested if F1 wt animals had an intermediate amount of CD103+
CD11b− DCs. This hypothesis could be confirmed in LP (Fig.5.17 A) of analyzed animals,
while wt animals of different genetic backgrounds did not differ in the frequency of the mLN
CD103+CD11b− DCs (Fig.5.17 B).
Additionally, the activation status of DCs in C57BL/6 and BALB/c animals after anti-
CD40 treatment was compared. Some differences between the two strains could be shown.
24 h after an anti-CD40 injection most of the DC subsets in LP or mLNs showed no change
in MHC II expression. Only CD103−CD11b+ cells in LP of BALB/c animals showed a slight,
albeit significant, down-regulation of MHC II expression. In contrast, a strong up-regulation
of CD80 and CD86 co-stimulatory molecules on mLN and LP DCs of both mice strains 24 h
after triggering the CD40 pathway was observed (Fig.5.18 A and B).
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Figure 5.16: Injection of an anti-CD40 antibody had a similar effect on the migration
of DCs in C57BL/6 and BALB/c wt animals. DC subsets in the LP (A) or mLN (B) were
analyzed in wt C57BL/6 and wt BALB/c animals injected with an anti-CD40 antibody (24 hours
post IP injection) and in un-injected controls of each mouse strain. A) Representative lamina
propria FACS-plots are shown, numbers and dot graphs indicate the frequency of DC subsets.
Shown are pooled statistics from 2 experiments (n = 5-6). B) Representative mLN FACS-plots
are shown, numbers and dot graphs indicate the frequency of DC subsets. Shown are pooled
statistics from 2 experiments (n = 5-6). C) CCR7 expression was analyzed in different subsets
of lamina propria DCs from wt C57BL/6 and wt BALB/c animals injected with the anti-CD40
antibody (IP injection, 24 hours) or untreated littermates controls. Shown are representative
histograms of isotype control staining (grey filled), controls (grey line) and anti-CD40 injected
animals (black line) for CCR7 staining in different subsets of LP DCs. Numbers on histograms
represent MFI ± SEM (which is additionally displayed in the bar graph on the right side) from
1 representative experiment (n = 3) of two independent experiments. All graphs represent mean
± SEM where significance was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01
and ***: P < 0.001. Ctr = control. Black stars indicate significance for C57BL/6 mouse strain,
while the red stars indicate significance for BALB/c mouse strain.
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Figure 5.17: BALB/c wt animals had the highest frequency of CD103+CD11b− DCs.
DC subsets in the LP (A) or mLN (B) were analyzed in wt (wild type) animals on different
genetic backgrounds. A) LP cells were gated on single cells, live, CD45+MHCII+CD11c+CD64−
cells. Representative FACS-plots are shown, numbers and bar graphs indicate the frequency of
DC subsets. Shown are pooled statistics from 2 experiments (n = 5-6). B) mLN cells were gated
on single cells, live, MHCII+CD11c+ cells. Representative FACS-plots are shown, numbers and
bar graphs indicate frequency of DC subsets. Shown are pooled statistics from 2 experiments
for C57BL/6 DC-LMP1/CD40 animals (n = 4-6). All bar graphs represent mean ± SEM where
significance was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P <
0.001.
In order to compare the activation profile of anti-CD40 injected animals of different genetic
backgrounds, the percentage of MFI from co-stimulatory molecules on each DC subset in
anti-CD40 injected animals was calculated. The MFI of the corresponding un-injected genetic
background control represented 100 % for the respective analyzed co-stimulatory molecule on
each specific DC subset. When the results were analyzed like this, it could be shown that
anti-CD40 injection in BALB/c animals activated DCs stronger as compared to C57BL/6
animals. Higher expression of CD80 and CD86 co-stimulatory molecules were observed on
CD40-treated DCs of BALB/c genetic background (Fig.5.19 A and B).
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Figure 5.18: DC maturation markers on mLN and LP DCs from anti-CD40 injected
C57BL/6 and BALB/c wt animals. DC subsets of the LP (A) or mLN (B) were analyzed
for the expression of different activation markers. Shown are representative histograms of wt
controls (filled grey) and anti-CD40 injected animals (black line). The numbers represent MFI
± SEM. A) Shown are pooled statistics for LP DCs from 2 experiments for anti-CD40 injected
(IP injection, 24h time point) C57BL/6 and BALB/c animals (n = 5-6). B) Shown are pooled
statistics for mLN DCs from 2 experiments for anti-CD40 injected (IP injection, 24h time point)
C57BL/6 and BALB/c animals (n = 5-6). The significance was analyzed using a students t-test,
with *: P < 0.05, **: P < 0.01 and ***: P < 0.001.
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Figure 5.19: Anti-CD40 treated animals on BALB/c genetic background showed
higher expression of CD80 and CD86 co-stimulatory molecules. DC subsets in the LP
(A) or mLN (B) were analyzed as described in figure 5.18. MFI values for activation markers
of each DC subset in different DC-LMP1/CD40 animals are shown as relative change to suitable
un-injected background control (red line represents average frequency of background control).
A) Relative calculations were performed for lamina propria samples shown in figure 5.18 A. B)
Relative calculations were performed for mLN samples shown in figure 5.18 B. The significance
was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P < 0.001.
5.3 Activated CD4 T cells trigger reduction of CD103+
DCs
In order to investigate a potential biological relevance of the observed mechanism we per-
formed the following experiment. CD40 ligand (CD154), the natural ligand for CD40, is
expressed on activated T cells in vivo [223]. We therefore tested the possibility if activated T
cells could induce migration of tolerogenic CD103+ DCs from LP to mLNs, as demonstrated
for CD40 antibody triggering or CD40 signaling in DC-LMP1/CD40 mice. Such a mecha-
nism has the potential to shut down tolerance induction in order to make ongoing immune
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responses more potent. To this end treg-depleted naïve CD62L+CD4+ T cells were trans-
ferred into Rag−/− animals. Since Rag−/− mice have no T cells, transferred T cells started
to spontaneously proliferate and became activated. Mice were analyzed 15 days after adop-
tive T cell transfer and it could be shown that the tolerogenic CD103+CD11b− DC subset
was significantly reduced in LP of experimental animals when compared to Rag−/− control
animals (Fig.5.20).
Taken together this experiment suggested that activated T cells have the potential to trigger
DCs in order to modulate tolerance versus immunity.
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Figure 5.20: Activated CD4 T cells had the capacity to induce migration of DCs from
LP. CD4+CD62L+ T cells from donor wild type C57BL/6 mice were transferred into Rag−/−
animals and subset distribution of lamina propria DCs was analyzed 15 days after transfer.
Shown are representative FACS plots with indicated frequencies of DC subsets. Bar graphs
represent the pooled statistics for frequencies and absolute numbers of DC subpopulations from
2 experiments (n = 6). All bar graphs represent mean ± SEM where significance was analyzed
using a students t-test, with *: P < 0.05, **: P < 0.01 and ***: P < 0.001. Ctr = control.
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5.4 SNP genotyping of F2 DC-LMP1/CD40 mouse
strain
F2 DC-LMP1/CD40 animals were a genetically and phenotypically heterogeneous group of
mice, where approximately 30 % of animals developed colitis while the rest remained healthy
(Fig.5.21 A). This heterogeneity was used for a SNP analysis, with the purpose to identify
candidate genes that might be key for different colitis susceptibility between C57BL/6 and
BALB/c. DNA samples were collected from F2 DC-LMP1/CD40 animals with visible signs of
colitis and a SNP genotyping with the Ilumina Mouse Linkage LD chip (Illumina, San Diego,
CA, USA) was performed. The Ilumina Mouse LD Linkage Panel covers 377 SNP loci chosen
to maximize genetic information across the top ten inbred strains routinely used for mouse
crosses. This genetic information could be used to eventually identify C57BL/6 SNP alleles
which contribute to disease in F2 DC-LMP1/CD40 mice with colitis. On the other hand it
could also allow the identification of BALB/c SNP alleles which eventually protect from colitis.
Only F2 DC-LMP1/CD40 animals with visible signs of colitis (colitis visible on macroscopic
level by colon shortening and thickening) were analyzed. This criteria fulfilled approximately
30 % of F2 DC-LMP1/CD40 animals (Fig.5.21 A). Since in addition to these 30 % of F2
DC-LMP1/CD40 animals only C57BL/6 DC-LMP1/CD40 animals developed colitis, it was
expected that the SNP study would lead to the identification of a region in the mouse genome
where all tested sick F2 DC-LMP1/CD40 animals would be homozygote for C57BL/6 SNP
allele. Although, there was no region homogeneous for the C57BL/6 SNP allele, a region
on mouse chromosome 2 was identified where all 60 analyzed F2 DC-LMP1/CD40 animals
carried at least one C57BL/6 derived allele (Fig.5.21 B). Since we relied on visible signs of
colitis and did not perform an extensive histology analysis for every mouse, the study design
might not have been precise enough and some F2 transgenic animals with milder colitis might
have been included. Therefore, we still took a deeper look in the identified SNP region of
chromosome 2, which led to the identification of 16 immunology relevant genes (Fig.5.21 C).
qPCR primers for each of these genes were designed to compare expression levels of these
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genes between C67BL/6 and BALB/c mice strains. All 11 different defensins have shown to
be hard to study with qPCR, because they showed a high degree of homology. The IL1bos,
CD93 and Fkbp1a genes were not followed further, since no connection between them and
colitis could be found. In contrast IL-1𝛼 and especially IL-1𝛽 got our attention. Both genes
were found to be significantly up-regulated in the inflamed colonic mucosa of patients with
ulcerative colitis [224, 225].
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Figure 5.21: SNP genotyping for the F2 DC-LMP1/CD40 genetically heterogeneous
mouse strain identified 16 candidate genes for different colitis susceptibility between
C57BL/6 and BALB/c mouse strain. A) Pie chart representing the percentage of F2
DC-LMP1/CD40 animals (generated with F1 DC-LMP1/CD40 inter-cross) with visible signs of
colitis (colitis visible on macroscopic level by colon shortening and thickening) (n = 223). B) SNP
analysis of F2 DC-LMP1/CD40 animals which developed colitis (n = 60) and control animals
to test the accuracy of SNP analysis. Magnified is a region on chromosome 2 that contains at
least one copy of the C57BL/6 allele for the analyzed SNP. C) List of immunologically relevant
genes within this region on the mice chromosome 2.
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5.4.1 Testing IL-1𝛼 and IL-1𝛽 as candidate genes for colitis
susceptibility
Due to its high potency to induce inflammation, the activation and secretion of IL-1𝛽 is tightly
regulated with the formation of inflammasomes [226]. On the other hand, the physiological
role in the inflammatory process and biogenesis of IL-1𝛼 are less well defined [227].
BMDC cultures from C57BL/6 and BALB/c mouse strains were prepared and stimulated
for 3 h with LPS in order to induce intra-cellular production of IL-1 cytokines, which were
not secreted in the medium if the inflammasome was not further triggered [228]. In the next
step LPS stimulated BMDCs were lysed and intracellular IL-1𝛼 and IL-1𝛽 cytokine levels
were measured with an ELISA assay. Interestingly, it could be shown that BMDCs from
C57BL/6 mice produced more IL-1𝛼 and IL-1𝛽 than BMDCs from BALB/c mice after they
were stimulated with LPS (Fig.5.22 A).
Additionally, the IL-1 family cytokine levels in DC-LMP1/CD40 transgenic animals were
analyzed. The whole gut homogenate samples from C57BL/6 DC-LMP1/CD40 and F1 DC-
LMP1/CD40 animals with suitable wt controls were prepared. The IL-1𝛼 and IL-1𝛽 cytokine
levels were measured with an ELISA assay. A high amount of both cytokines could be
detected in the gut samples from C57BL/6 DC-LMP1/CD40 animals, while no signal could
be detected in transgenic animals on F1 background or in control wt animals (Fig.5.22 B).
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Figure 5.22: IL-1 cytokines were potential candidates for different colitis suscep-
tibility between mouse strains. A) The amount of IL-1𝛼 and IL-1𝛽 was determined by
ELISA in lysates of C57BL/6 and BALB/c BMDCs with and without LPS stimulation. Shown
are representative results from one of 2 independent experiments with similar outcome (n = 3).
B) The amount of IL-1𝛼 and IL-1𝛽 was determined by ELISA in whole colon homogenates of
C57BL/6 and F1 DC-LMP1/CD40 animals with suitable controls for each background. The
measured amount of cytokine was normalized on the starting amount of each sample. Shown are
representative results from one of 2 independent experiments with a similar outcome (n = 4). All
bar graphs represent mean ± SEM where significance was analyzed using a students t-test, with
*: P < 0.05, **: P < 0.01 and ***: P < 0.001. n.d. = not detectable; un. = un-stimulated;
LPS = lipopolysaccharides.
Taken together we could show that C57BL/6 derived BMDCs responded on LPS stimu-
lation with higher production of IL-1𝛼 and IL-1𝛽 cytokines than BALB/c derived BMDCs.
Additionally, we could measure high levels of IL-1𝛼 and IL-1𝛽 cytokines only in whole gut
homogenate samples from C57BL/6 DC-LMP1/CD40, while no signal could be detected in
F1 DC-LMP1/CD40 or in F1 and C57BL/6 wt animals. However, it is important to be aware
that the difference in IL-1 cytokine level between transgenic C57BL/6 and F1 animals is also
due to inflammation, which is going on only in transgenic C57BL/6 animals. Therefore, it is
hard to say if IL-1 is causative or it is just a consequence of the disease.
Using data-set from the Mouse Genome Database SNPs in IL-1𝛼 and IL-1𝛽 that were
discriminatory between C57BL/6 and BALB/c were identified. Two SNPs were located in
the IL-1𝛽 gene and one in the IL-1𝛼 gene (Fig.5.23 A). All these three SNPs were located in
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the non coding three prime untranslated region, which is known to influence polyadenylation,
translation efficiency, localization, and stability of mRNA [229, 230]. Therefore, we tested
if there was a potential correlation between the SNP in genetically heterogeneous F2 DC-
LMP1/CD40 animals with or without disease development. Primers were designed to amplify
the SNPs containing regions and these were amplified from F2 DC-LMP1/CD40 animals. The
PCR products were run on the agarose gel and the suitable bands representing one of the IL-1
gene segments including SNPs were cut out and sequenced. Sequencing data was analyzed
and the SNP in IL-1𝛽 gene with the number rs3022903 gave a clear reliable sequence, while
the others did not.
The idea was to search for a correlation between C57BL/6 origin of SNP in the IL-1𝛽 gene
and the development of colitis. As a marker of colitis fecal lipocalin-2 was used. In this part
of the study every F2 DC-LMP1/CD40 animal, which was sequenced for IL-1𝛽 SNP, was
also measured for fecal lipocalin-2. The expectation was that animals with the high levels of
lipocalin-2, meaning animals with strong intestinal inflammation, would carry the C57BL/6
allele for SNP in IL-1𝛽 locus. However, this was not the case (Fig.5.23 B). Only one F2 DC-
LMP1/CD40 animal was found to be a homozygot for allele derived from BALB/c strain,
while many animals carried one C57BL/6 and one BALB/c allele. Since those heterozygous
mice had the same level of inflammation like the animals carrying two C57BL/6 alleles, we
could not confirm our hypothesis.
The reason for the negative result could have been a less than ideal choice of marker for
the presence of colitis. Therefore, it was decided to directly measure the level of IL-1𝛽 in
whole gut homogenate of F2 DC-LMP1/CD40 animals and then correlate these levels with
the genetic origin of the SNP in the IL-1𝛽 gene locus. This kind of analysis also failed to
prove the hypothesis that C57BL/6 origin of IL-1𝛽 gene could have been responsible for high
levels of IL-1𝛽 cytokine in C57BL/6 DC-LMP1/CD40 animals (Fig.5.23 C).
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Figure 5.23: Sequencing of IL-1 locus in F2 DC-LMP1/CD40 animals, in order to
confirm C57BL/6 derived IL-1𝛽 allele as reason that animals develop colitis. A) SNPs
located in mouse IL-1 locus on chromosome 2, for which C57BL/6 mouse strain has different
allele than BALB/c mouse strain. For all this SNPs sequencing primers were generated, but
they worked only for the second SNP in IL-1𝛽 gene (rs3022903). B) Levels of fecal lipocalin-2
as measured by ELISA in 10-12 weeks old F2 DC-LMP1/CD40 in relation with sequencing data
for rs3022903 SNP in IL-1𝛽 locus. The dot plot represents data acquired from 38 experimental
animals. C) Levels of IL-1𝛽 as measured by ELISA in whole colon homogenates (measured
amount of cytokine was normalized on the starting amount of each sample, measured in grams)
of 10-12 weeks old F2 DC-LMP1/CD40 in relation with sequencing data for rs3022903 SNP in
IL-1𝛽 locus. The dot plot represents data acquired from 29 experimental animals. All graphs
represents mean ± SEM where significance was analyzed using a students t-test, with *: P <
0.05, **: P < 0.01 and ***: P < 0.001.
5.5 Blocking IL-1𝛽 prevented colitis development in
C57BL/6 transgenic mice
Since high levels of IL-1𝛽 cytokine could be measured only in C57BL/6 DC-LMP1/CD40
animals, which developed strong intestinal inflammation, rescue of the animals by blocking
the IL-1𝛽 cytokine with an anti IL-1𝛽 antibody was attempted. The amount of injected
antibody was titrated and the length of the experiment was optimized. Five weeks old
C57BL/6 DC-LMP1/CD40 animals, which have been treated with ABX to prevent onset of
colitis, were moved to cages containing feces from the rest of the mouse facility for commensal
bacteria repopulation and ABX treatment was stopped. Doing this we exposed C57BL/6 DC-
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LMP1/CD40 animals to bacteria, which caused colitis development in untreated C57BL/6
DC-LMP1/CD40 animals. Simultaneously, we started treatment of experimental mice with
an anti-IL-1𝛽 antibody, which was injected twice per week intraperitoneally. The control
mice were treated with an isotype control antibody. Treatment lasted for 7 weeks (Fig.3.2
A). The weight of treated and control mice was regularly measured (not shown) and at the
end of the experiment it could be shown that anti-IL-1𝛽 treatment protected C57BL/6 DC-
LMP1/CD40 animals from wasting disease. Their average weight was significantly higher
than the weight of the isotype control treated mice (Fig.5.24 C). Also macroscopic photos of
the colon revealed that the anti-IL-1𝛽 treatment protected C57BL/6 DC-LMP1/CD40 from
colitis development (Fig.5.24 B). Colons from isotype treated animals were shorter and visibly
more inflamed. Additionally, the absence of inflammation by measuring the fecal lipocalin-
2 levels [221] could be shown. In contrast to anti-IL-1𝛽 treated animals, isotype treated
C57BL/6 DC-LMP1/CD40 mice showed high levels of lipocalin-2 (Fig.5.24 D).
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Figure 5.24: Anti-IL-1𝛽 treatment could prevent colitis development in C57BL/6
DC-LMP1/CD40 animals. A) Anti-IL-1𝛽 treatment experiment design. C57BL/6 DC-
LMP1/CD40 mice were born on ABX therapy and were drinking ABX water until the age of
5 weeks. Then the mice were transferred into a dirty cage and the treatment with an anti-
IL-1𝛽 antibody or isotype ctr antibody was started. 0.25 mg of antibody was intraperitoneally
injected twice per week for duration of 7 weeks. The day later mice were sacrificed and analyzed.
B) Macroscopic pictures of colons from isotype control and anti-IL-1𝛽 treated C57BL/6 DC-
LMP1/CD40 animals after 7 weeks of therapy. Bar = 1 cm. C) Weight of mice measured at
the end of experiment. Shown are pooled statistics from 2 experiments (n = 8-10). D) Levels of
fecal lipocalin-2 as measured by ELISA in the experimental animals at the end of experiment.
Shown are pooled statistics from 2 experiments (n = 8-10). All bar graphs represent mean ±
SEM where significance was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01
and ***: P < 0.001. Ctr = control, Ab = antibody, IP = intraperitoneal.
5.6 Blocking IL-1𝛽 prevented the expansion of IFN-𝛾+ T
cells
After it was shown that anti-IL-1𝛽 treatment prevented colitis development in C57BL/6 DC-
LMP1/CD40 mice, it was analyzed if it also prevented the expansion of pathogenic IFN-𝛾+
T cells, which probably caused colitis in C57BL/6 DC-LMP1/CD40 animals.
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No difference in frequency or absolute number of IL-17+IFN-𝛾− and IL-17+IFN-𝛾+ lamina
propria effector T cells between C57BL/6 DC-LMP1/CD40 treated with anti-IL-1𝛽 mAb or
isotype control antibody could be detected. However, a decrease in the frequency and in the
number of IL-17−IFN-𝛾+ T cells could be observed (Fig.5.25 A). These IL-17−IFN-𝛾+ T cells
are the effector cell subset which was increased only in C57BL/6 DC-LMP1/CD40 animals
while they could not be identified in transgenic animals on F1 or BALB/c genetic backgrounds
(Fig.5.11 and Fig.5.12). Therefore, this suggested that they were the ones responsible for
colitis development.
Analysis of the mLNs gave a similar result as described for LP, with the only difference
being that here only the decrease in the absolute number of IL-17−IFN-𝛾+ T cells could be
seen, while anti-IL-1𝛽 treatment did not affect their frequency (Fig.5.25 B).
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Figure 5.25: Anti-IL-1𝛽 treatment strongly reduced the development of IL-17−IFN-
𝛾+ CD4 T cells. T cell functionality was analyzed by stimulating single cell suspensions of
lamina propria cells (A) or mLN cells (B) from C57BL/6 DC-LMP1/CD40 animals, which were
treated with anti-IL-1𝛽 or with isotype control, with PMA/Ionomycin for 4 h and subsequently
staining cells intracellular for the production of IL-17 and IFN-𝛾. A) Shown are representative
FACS-plots with indicated frequencies for LP (gated on single, live, CD45+CD3+CD4+). Bar
graphs represent pooled statistics from 2 experiments (n = 5-7). B) Shown are representative
FACS-plots with indicated frequencies for mLN (gated on single, live, CD3+CD4+). Bar graphs
represent pooled statistics from 2 experiments (n = 6-9). All bar graphs represent mean ± SEM
where significance was analyzed using a students t-test, with *: P < 0.05, **: P < 0.01 and
***: P < 0.001. Ctr = control, Ab = antibody, IP = intraperitoneal.
5.7 LMP1/CD40 transgene induces IL-12-p35
production in CD64+ macrophages
After showing that high levels of IL-1𝛽 could only be detected in colitis C57BL/6 DC-
LMP1/CD40 mice (Fig.5.22 B) and that an anti-IL-1𝛽 treatment prevented the disease in
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these animals (Fig.5.24), we wanted to identify the cell population which produced IL-1𝛽.
Since the production of IL-1𝛽 could only be detected in transgenic animals, all cell popula-
tions expressing the LMP1/CD40 transgene were analyzed. These were CD11c+ cells, which
are mostly DCs and macrophages. Surprisingly the expression of IL-1𝛽 RNA could not be de-
tected in CD103+ DCs nor in CD103− DCs (Fig.5.26 A). However, when CD64+ macrophages
were sorted from LP of control and transgenic animals, it could be seen that DC-LMP1/CD40
animals on C57BL/6 genetic background produced high amounts of IL-1𝛽 (Fig.5.26 B, upper
panel). Interestingly, an increase in the amount of IL-1𝛽 in CD64+ macrophages derived
from F1 and BALB/c transgenic animals could not be observed (Fig.5.26 B). In order to test
if observed difference in IL-1𝛽 expression was mouse strain background dependent, CD64+
macrophages from ABX treated C57BL/6 DC-LMP1/CD40 animals were analyzed. How-
ever, in these animals increased levels of IL-1𝛽 could not be detected (Fig.5.26 B, lower
panel). Additionally, high levels of IL-23-p19 and IL-12-p35 could be measured in CD64+
macophages from C57BL/6 transgenic animals, while these two cytokines were increased to
a smaller extend in CD64+ macophages from F1 transgenic animals. In contrast BALB/c
DC-LMP1/CD40 animals and ABX treated C57BL/6 DC-LMP1/CD40 animals only showed
elevated levels of IL-12-p35 cytokine, what suggested that elevation of this cytokine was di-
rectly caused by LMP1/CD40 transgene, since in these two strains no inflammation could be
detected (Fig.5.1 for BALB/c DC-LMP1/CD40 animals and [208] for ABX treated C57BL/6
transgenic animals).
Taken together, cytokine profiles of LP macrophages in transgenic animals of different ge-
netic origins revealed that macrophages in C57BL/6 DC-LMP1/CD40 animals showed the
most inflammatory phenotype, while these from F1 DC-LMP1/CD40 animals and especially
these from BALB/c DC-LMP1/CD40 animals showed less inflammatory one. High levels
of IL-12-p35 cytokine were directly caused by LMP1/CD40 transgene, since this cytokine
was measured at elevated levels also in BALB/c transgenic animals and in ABX treated
C57BL/6 transgenic animals. Hovewer, elevated levels of IL-23-p19 and IL-1𝛽 in C57BL/6
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DC-LMP1/CD40 animals were according to these results caused by some secondary inflam-
matory effect, since ABX treatment reduced their levels on levels present in wt C57BL/6
animals.
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Figure 5.26: CD64+ macrophages produced IL-23p19, IL-1𝛽 and IL-12-p35 in
C576BL/6 DC-LMP1/CD40 animals upon inflammation, while only IL-12-p35 pro-
duction was directly caused by LMP1/CD40 transgene. A) CD103+ and CD103− DCs
were sorted from mLNs (single, live, MHCII+CD11c+CD64−) of C57BL/6 control and C57BL/6
DC-LMP1/CD40 animals. Trizol RNA isolation protocol was used for RNA isolation, from which
cDNA was prepared. Samples were analyzed by qPCR and data was normalized on HPRT expres-
sion. Shown is pooled data (n = 6-9). B) CD64+ macrophages were sorted from LP (single, live,
CD45+MHCII+CD11c+CD64+) of C57BL/6 DC-LMP1/CD40, F1 DC-LMP1/CD40, BALB/c
DC-LMP1/CD40 and ABX treated C57BL/6 DC-LMP1/CD40 animals. Control group for each
mice strain background and ABX therapy was included. Trizol RNA isolation protocol was used
for RNA isolation, from which cDNA was prepared. Samples were analyzed by qPCR and data
was normalized on HPRT expression. Shown is pooled data (n = 4-10). All bar graphs represent
mean ± SEM where significance was analyzed using a students t-test, with *: P < 0.05, **: P
< 0.01 and ***: P < 0.001. Ctr = control, ABX = antibiotics.
6 Discussion
The fact that genetic background of mouse strains can influences the outcome of experiments
has been shown for many different autoimmune diseases before. Different genetic mutations
and polymorphisms are the reasons for divergent patterns of immune responses and conse-
quently a different susceptibility to diseases between mouse strains. Conventional transgenic
and gene knockout technologies have enabled modeling of human diseases in experimental
mice. However, when phenotyping genetically modified mice it is important to consider that
targeted genes may not solely contribute to the outcome of the experiments. It is important
to be aware of the effect of strain background, microbial milieu, environmental and epigenetic
factors [231].
In recent years our group has been studying the constitutive CD40-triggering of DCs, its
effects on DCs maturation, on DCs homeostasis and on peripherial tolerance induction [208].
We used the advantage of transgenic mice expressing a LMP1/CD40 transgene [209]. Due
to breeding LMP1/CD40 transgenic mice to CD11c Cre animals, only CD11c+ cells such as
DCs and macrophages [213] do express the transgene.
Initial experiments have been done with C57BL/6 DC-LMP1/CD40 animals, for which
we have shown that the constitutive triggering of the CD40 pathway induced a migration
of tolerogenic DC subsets from LP to mLNs. This led to a reduction of CD103+CD11b−
and CD103+CD11b+ DCs (Fig.3.1 B), was accompanied by a strong reduction of Helios−
peripherial induced Treg cells (Fig.3.2 A) and resulted in a breakdown of intestinal tolerance
with increased amounts of IL-17+IFN-𝛾+ and IFN-𝛾+ T cells in lamina propria of transgenic
animals (Fig.3.2 B) [208]. Colonic Tregs in these animals could not regulate the inflam-
matory response against commensal bacteria, which caused a colitis-like phenotype and a
drastically shortened life lifespan of C57BL/6 DC-LMP1/CD40 mice (Fig.3.1 A). However,
DC-LMP1/CD40 transgenic animals in the BALB/c and in mixed C57BL/6 x BALB/c back-
grounds (here called F1 DC-LMP1/CD40 animals) surprisingly did not develop any intestinal
pathology (nor any other) (Fig.5.1 A and C). This observation further confirmed the point
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of the paper by the Sellers group [231], where they warn that immunological variation be-
tween inbred laboratory mouse strains can have a big influence on phenotyping results from
genetically modified mice.
BALB/c and C57BL/6 mice are two of the most commonly used inbred mouse strains which
are well known to have different immune responses. While differences in disease susceptibility
do not come as a surprise, the elucidation of the underlying reasons may help in understanding
the molecular cause and thereby help in developing novel treatments.
Several differences between C57BL/6 and BALB/c animals have been described. BALB/c
are albino mice and are of the H2𝑑 MHC haplotype, while C57BL/6 have black fur and a H2𝑏
MHC haplotype. A study which compared inbred mice of congenic strains that differ only in
their H2 haplotypes has shown the effect of haplotype on the production of several cytokines.
Cells from mice with H2𝑏 MHC haplotype responded to in vitro mitogen stimulation with
lower levels of IL-3, IL-4, IL-5, TNF, IL-6 and IL-10 [232].
Additionally, one big difference between those two strains lies in the Th1/Th2 induction
capacity [233]. It was demonstrated that C57BL/6 is a prototypical Th1 mouse strain, whose
macrophages upon activation produce more TNF-𝛼, IL-12 and IFN-𝛾 than BALB/c mice,
which have a more Th2 directed immune response with a higher production of IL-4 [234,
235]. A different pattern of cytokine production makes BALB/c mice more susceptible to
intracellular parasite infections. A good example for that is experimental infection with
the intracellular protozoan Leishmania major, where the Th1 directed immune response of
C57BL/6 mice offers good protection, while the Th2 directed immune response of BALB/c
mice is not efficient [236].
On the other hand this type of immune response makes BALB/c mice more resistant to
autoimmune diseases such as experimental autoimmune encephalomyelitis (EAE) [237, 238],
experimental autoimmune myasthenia gravis [239] and experimental autoimmune uveitis [240,
241, 242] when compared to a highly susceptible C57BL/6 mouse strain.
Another study, which compared Treg cells between BALB/c and C57BL/6 mouse strains,
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showed that BALB/c mice have more Tregs than C57BL/6 mice and that CD4+CD25− (re-
sponder) T cells from C57BL/6 mice are in addition notably less susceptible to suppression
by Treg cells [243]. However, it is important to mention that this study did not use FoxP3
as a marker to identify Treg cells. In this study all CD25+ cells were assumed to be Tregs,
which is according to modern standards not a correct definition anymore, as CD25 is also
expressed on all activated T cells [244].
Observations from all these studies highlight the importance of the mouse genetic back-
ground in the planning and interpretation of the immunological studies. The above listed
differences in immune response between C57BL/6 and BALB/c mouse strain could at least in
part contribute to the differences in colitis susceptibility between DC-LMP1/CD40 animals on
different genetic backgrounds. However, the purpose of this thesis was to precisely analyze the
phenotypical differences between DC-LMP1/CD40 animals on different genetic backgrounds
with the goal to identify the exact reason why only C57BL/6 mouse strain develop colitis
upon constitutive triggering of the CD40 pathway.
6.1 Phenotypic analysis of DC-LMP1/CD40 animals on
different genetic backgrounds
The experiments with DC-LMP1/CD40 animals have shown that transgenic animals on
C57BL/6 genetic background developed a colitis-like phenotype, which depended on lympho-
cytes and commensal bacteria, since RAG−/− C57BL/6 DC-LMP1/CD40 and ABX treated
C57BL/6 DC-LMP1/CD40 animals were protected from disease development (Fig.3.1 and
5.1).
From human patients it is known that ulcerative colitis develops in genetically susceptible
individuals, due to an inappropriate immune response towards normal gut micro-flora. It
was shown that genetic mutations, which increase intestinal barrier permeability lead to a
higher risk for disease development [245]. The very same mechanism is used in dextran sulfate
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sodium induced model of colitis [246] where mice develop a colitis-like phenotype, which is
most likely the result of damage in the intestinal epithelial mono-layer and the penetration
of bacteria into gut lamina propria. Similarly, like in our DC-LMP1/CD40 colitis model, also
in colitis model of DSS [247] as well as in IL-10 gene-deficient mice [248] ablation of bacteria
with ABX significantly improved clinical and histopathological severity of disease.
What is more interesting than the dependency of colitis development on bacteria is that
only C57BL/6 animals developed an intestinal pathology as a result of constitutive CD40
stimulation (Fig.5.1). In DC-LMP1/CD40 animals on F1 genetic background no inflammation
could be observed on a macroscopic level, while histological analysis has shown only minor
changes. Analysis with the non-invasive inflammatory marker lipocalin-2 [221] confirmed that
inflammation is highly present in C57BL/6 DC-LMP1/CD40 animals, while F1 transgenic
animals showed only slightly increased levels of fecal lipocalin-2 (Fig.5.1 C). In contrast,
BALB/c transgenic animals showed no visible signs of inflammation, nor did they have an
increased amount of fecal lipocalin-2 (Fig.5.1 C).
When differences between DC-LMP1/CD40 animals on a molecular level were searched for
and the colon cytokine profile of transgenic animals on C57BL/6 and F1 genetic backgrounds
was analyzed, yet again changes were observed only in C57BL/6 transgenic animals (when
compared to controls). Whole gut homogenate samples of C57BL/6 DC-LMP1/CD40 animals
have shown a significant increase of pro-inflammatory cytokines MCP1, TNF-𝛼, IFN-𝛾 and IL-
6, while anti-inflammatory IL-10 was significantly reduced (Fig.5.2). Increased inflammatory
cytokine levels including TNF-𝛼 and IL-6 have previously been connected with pathogenesis of
colitis [249], where treatment with the TNF-𝛼 blockers has proven to be beneficial for patients
[250, 251]. For MCP1 is known that it regulates the migration of monocytes from the blood
across the vascular epithelium, which is an important factor for the onset of inflammation
[252]. Therefore, high levels of MCP1 in C57BL/6 DC-LMP1/CD40 animals might contribute
to the extensive lamina propria infiltration of mixed inflammatory mononuclear cells, which
could be observed in these animals, while they could not be seen in F1 transgenic animals.
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On the other hand IL-12 is known to promote Th1 immune responses and INF-𝛾 production,
where its blocking was shown to prevent spontaneous colitis in IL-10 deficient mice [253].
The absence of IL-12-p70 cytokine increase in whole gut homogenate samples of C57BL/6
transgenic animals (Fig.5.2) is in conflict with the qPCR data from CD64+ macrophages in
this animals, which showed a significant increase in the expression of IL-12p35 (Fig.5.20),
which is a sub-unit of IL-12-p70. Even if high levels of IL-12 in C57BL/6 transgenic animals
would help to explain high frequencies of IL-17−IFN-𝛾+ T cells present only in transgenic
animals of C57BL/6 origin, the data obtained with CBAs are more informative, since it is
known that many post-transcriptional mechanisms control the final protein abundance [254].
However, since pro-inflammatory cytokines were not measured in whole gut homogenate
samples of ABX treated C57BL/6 DC-LMP1/CD40 animals, the factor of inflammation in
C57BL/6 DC-LMP1/CD40 animals can not be excluded. Latter makes it impossible to
differentiate if elevated pro-inflammatory cytokine levels were a cause for the disease or were
actually its consequence.
6.1.1 Reduction of tolerogenic CD103+ DCs was independent of the
genetic background
The effect of CD40 signaling on CD103+ DCs was first shown by the group of Fiona Powrie.
In this study CD40 stimulated sorted DCs down regulated CD103 expression and anti-CD40
injection into Rag−/− mice decreased CD103+MHCII+ cells in the spleen and caused wasting
disease with colitis [142]. Because of this finding and the constant CD40 signaling in our trans-
genic mice, CD103+ DC subsets have been analyzed. We recently published that C57BL/6
DC-LMP1/CD40 animals had a strong reduction of CD103+CD11b− and CD103+CD11b+
DCs, while CD103− DCs were increased. However, the increase of CD103− DCs was a sec-
ondary inflammatory effect and not a direct effect of the LMP1/CD40 transgene, since it
was not the case in ABX treated animals or in Rag−/− animals [208]. The comparison of
C57BL/6 DC-LMP1/CD40 animals with transgenic animals on partial or complete BALB/c
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genetic backgrounds has shown that a reduction of CD103+ tolerogenic DCs was background
independent (Fig.5.3 A and B). The latter made the fact that these animals did not develop
the disease even more interesting. However, the percentage of remaining CD103+ DCs was
higher in transgenic animals with partial or complete BALB/c genetic backgrounds. Since
transgenic animals were on a different genetic backgrounds, the direct comparison between
the frequency of DC subsets was not possible. Therefore we calculated the percentage of
DCs subset in transgenic animals with the background controls providing a reference point
of 100 percent. Relative frequencies calculated in that way allowed us to compare between
DC-LMP1/CD40 transgenic animals on different genetic backgrounds and we could show
that CD103+CD11b− DCs were the most reduced in C57BL/6 transgenic animals (Fig.5.5).
From the recently published study of Esterhazy et al. it is known that this CD103+CD11b−
DC subset is the one with the highest tolerogenic properties as it expresses the highest lev-
els of Aldh1a2, Tgfb2 and Itgb8, enzymes crucial for Treg cells induction and imprinting of
gut homing [114]. Differences in the frequency of LP CD103+CD11b+ DCs between different
transgenic animals could not be found. However, it could be demonstrated that BALB/c DC-
LMP1/CD40 animals had the highest frequency of these cells in mLNs, while the frequency
in C57BL/6 transgenic animals was the lowest. This CD103+ DC subset was shown to be
less efficient in Treg induction due to different gene signature with other isoforms of Aldh1a2,
Tgfb2 and Itgb8 genes expressed [114]. Additionally, a relative increase of LP CD103− DCs
in C57BL/6 transgenic animals when compared to transgenic animals of other backgrounds
could be observed. As already mentioned, we assume that this increase was a secondary
effect of the inflammation, since this DC subset was only slightly increased in ABX treated
C57BL/6 DC-LMP1/CD40 animals [208]. The latter suggests that the pro-inflammatory mi-
lieu in C57BL/6 DC-LMP1/CD40 mice caused changes in the migration and renewal of this
heterogeneous and less well described DC subset, while inflammation was significantly weaker
in F1 and not detectable in BALB/c transgenic animals and therefore also CD103− DCs were
less increased.
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In DC-LMP1/CD40 transgenic animals all CD11c expressing cells received constant CD40
signaling, therefore it was interesting that only CD103+ DCs were reduced. We wanted
to show, that the observed difference stems from differences in the biology between DCs
subsets and not from a difference in the expression of the LMP1/CD40 transgene between
DCs subpopulations. The comparison in the expression of LMP1/CD40 transgene between
CD103+ and CD103− sorted DCs from LP of transgenic animals has shown that the transgene
was also expressed in CD103− DCs. Expression was even higher as compared to the CD103+
DCs (Fig.5.4), which suggests a different sensitivity of DC subsets to CD40 stimulation.
Some studies have reported that CD40 signaling improves the antigen presenting potential
of stimulated DCs with an up-regulation of MHC class II and co-stimulatory molecules like
CD80 and CD86 [129, 130, 131], whilst others have published that CD40 signaling alone
is not sufficient for the complete maturation of DCs, because it only induces the secretion
of IL-12-p40 and not its bioactive heterodimer IL-12-p70 [135]. When it was analyzed if the
expression of LMP1/CD40 transgene induced DCs maturation and if the degree of maturation
differed between C57BL/6 and F1 transgenic animals, a slight background independent up-
regulation of the CD80 co-stimulatory molecule on LP DCs could be found. Additionally,
a strong down-regulation of MHC II molecule on DCs, which was stronger for C57BL/6
transgenic animals, was observed (Fig.5.6). All studies [129, 130, 131] which reported that
CD40 signaling causes up-regulation of MHC class II molecule on DCs, were performed in
vitro. Therefore, the inconsistency between our observations and results from in vitro studies
probably arises from distinctive maturation of in vitro versus in vivo anti-CD40 matured
DCs. The phenomen which has previously been reported by the group of Frleta et al. [255].
However, the differences probably also arise from the fact that stimulation with CD40 mAb
gives a short strong stimulation, while LMP1/CD40 transgene results in constant stimulation
of CD40 pathway. Therefore, the DCs in DC-LMP1/CD40 animals might be in some way
adapted to the constant CD40 stimulus, since the intensity of signal stays unchanged.
The next interesting observation was that mLNs CD103+CD11b− DCs of both transgenic
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strains showed a down-regulation of CD86 co-stimulatory molecule. This was also not con-
sistent with the existing literature about the effects of anti-CD40 mAb on the maturation of
DCs. Frleta et al. reported that in vivo anti-CD40 matured DCs up-regulated CD86, which
peaked around day 2-3 and then declined to baseline level [255]. However, they were only
analyzing splenic DCs, while we were interested in mLN and LP DCs, and they stimulated
cells with an anti-CD40 antibody, while DCs in our transgenic animals were stimulated due
to the genetic construct. The latter is probably the reason for the differences between our
observations.
Experiments with C57BL/6 and F1 transgenic animals have shown that DCs in both mouse
strains showed similar activation profile. Besides the differential down-regulation of MHC
II molecule, no major differences could be observed. This effect was most likely due to
inflammation in C57BL/6 but not in F1 transgenic animals.
Lower levels of the CD86 co-stimulatory molecule on the most tolerogenic CD103+CD11b−
DCs subset [114] as well as an overall strong reduction of CD103+ DCs should have an effect
on the peripheral immune tolerance, therefore this was our next question to be approached.
6.1.2 DC-LMP1/CD40 mice lack iTreg cells
In our recently published paper we reported that C57BL/6 DC-LMP1/CD40 animals had
strongly reduced frequencies of ROR𝛾t+Helios− iTreg cells (Fig.3.2 A). Since F1 and BALB/c
DC-LMP1/CD40 transgenic animals did not develop intestinal inflammation, we analyzed if
they also lack iTreg cells. We confirmed that Helios− iTreg cells were reduced in the LP of all
DC-LMP1/CD40 animals when compared with controls of the same strain (Fig.5.8). However,
as with CD103+ DCs, Helios− iTreg cells were also the most reduced in C57BL/6 transgenic
animals, while in F1 transgenic animals and especially in BALB/c transgenic animals they
were present in significantly higher frequencies (Fig. 5.9). This finding would be in line with
the lowest frequencies of the most tolerogenic [114] CD103+CD11b− DCs subset in animals
on the C57BL/6 background. CD103+ DCs were shown to have a unique capacity to induce
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Foxp3 Treg cells from naïve CD4+ T cells in the periphery, due to their high expression
of the enzyme aldehyde dehydrogenase, which converts vitamin A into retinoic acid, and
high expression of tissue plasminogen activator, transforming growth factor-beta 2 and latent
TGF-𝛽-binding protein 3 [107, 111, 108]. We have shown that in C57BL/6 DC-LMP1/CD40
animals the total amount of Foxp3+ Tregs cells were not changed, when compared with
controls [208]. What was changed, was the ratio between nTreg and iTreg cells.
iTreg cells develop in the periphery from naïve CD4+ T cells and have been shown to be
crucial for a balance between pro- and anti-inflammatory mechanisms at mucosal interfaces of
the gastrointestinal tract, where the immune system comes in close contact with commensal
bacteria and food antigens [256]. Their enhanced suppressive capacity and superiority over
nTreg cells in gut-specific immune responses has recently been proven in the T-cell transfer
colitis model [257]. Therefore, high frequencies of nTreg cells in DC-LMP1/CD40 animals
could not compensate for the loss of iTreg cells, since the TCR of iTregs cells are of different
specificity and are shaped by local microflora [27, 30].
We were able to show that there was indeed a strong correlation between the frequency of
CD103+ tolerogenic DC subsets and the frequency of iTreg cells in the colon lamina propria
and in the mLNs (Fig.5.10). Analysis of the CD103−CD11b+ DCs has shown a negative
correlation with iTreg cells in LP and in mLNs (Fig.5.10), what is consistent with literature
where CD103− DCs are described as being more inflammatory and not efficient in inducing
iTreg cells [108, 111].
All these observations and reports from other studies suggested that a higher frequency of
CD103+ DCs in F1 and BALB/c DC-LMP1/CD40 animals seemed to be sufficient for a partial
induction of iTreg cell compartment, which managed to control the immune response against
commensal bacteria and has prevented colitis development in these animals. However, the
question why constitutive CD40 signaling affected CD103+ DCs of F1 and BALB/c animals
to a smaller extent than CD103+ DCs of C57BL/6 animals, remains unanswered.
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6.1.3 C57BL/6 DC-LMP1/CD40 mice showed a breakdown of
intestinal tolerance
The gastrointestinal tract is the place where the immune system comes in close contact with
food antigens and with a diverse microbial ecosystem. It is known that the microflora of a
healthy human contains more than 100 trillion microorganisms with a genome which is 100
times larger than the whole human genome [258]. In the gastrointestinal tract, the immune
system faces a complex population of beneficial commensal bacteria, which even though they
are foreign to the body, do not trigger the immune response in healthy individuals. Therefore,
the ability of the immune system to differentiate commensal bacteria from pathogens seems
even more remarkable. As far back as in 1995 the group of Duchmann et al. published that
normal individuals are tolerant to their own microflora, while they respond to the bacteria
of others. However, this is not the case for patients with IBD, who are not tolerant to their
own microflora [259].
The breakdown of intestinal tolerance could also be observed in C57BL/6 DC-LMP1/CD40
animals and it resulted in strong intestinal inflammation, which could be prevented by a de-
pletion of bacteria achieved with antibiotics. In transgenic animals with colitis an exacerbated
inflammatory Th17/Th1 T cell response could be seen [208]. The latter was most likely a
consequence of their lack of iTreg cells, which are known to be crucial for immune cell home-
ostasis and prevention of uncontrolled expansion of effector T cells against harmless antigens
[260]. iTreg and Th17 cell responses in the intestine are supposed to be reciprocally regulated,
to enable efficient inflammatory responses during host defense [261]. Both T cell populations
require TGF-𝛽 for their development, while additional IL-23 and IL-6 signaling promotes
differentiation to Th17 cells [262, 263].
In F1 DC-LMP1/CD40 animals a different distribution of T cell subsets has been found.
Here, in contrast to C57BL/6 DC-LMP1/CD40 animals IFN-𝛾+ T cells were not elevated,
while increased amounts of IL-17+ T cells were found in the LP (Fig.5.11). In contrast,
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BALB/c DC-LMP1/CD40 animals did not differ from BALB/c wt controls in their T cell
subset distribution.
It is known that Th17 cells are not a homogeneous group of cells, since they can be protective
[171] or they can be responsible for the development of autoimmune diseases [172]. Th17
cells differentiated only with TGF-𝛽1 and IL-6 are protective [173, 175], whilst their further
differentiation with IL-23 [176, 163] results in pathogenic Th17 cells, which express T-bet
[176, 163]. Considering this, it might be possible that Th17 cells, which were seen in F1 DC-
LMP1/CD40 animals, could be the protective Th17 subset. In order to better characterize
them, the T-bet levels in IL-17+IFN-𝛾− T cells from C57BL/6 and F1 DC-LMP1/CD40
animals were analyzed. We were able to show that IL-17+IFN-𝛾− T cell subset in C57BL/6
DC-LMP1/CD40 animals had a significantly higher expression of T-bet when compared to IL-
17+IFN-𝛾− T cells from C57BL/6 controls. However, this phenomen could not be observed
in IL-17+IFN-𝛾− T cells from F1 transgenic animals (Fig.5.14 B). The latter suggested a
higher degree of pathogenicity for IL-17+IFN-𝛾− T cells of C57BL/6 origin. It has been
published that Th17 cells can start expressing IFN𝛾 and in some inflammatory settings even
stop expressing IL-17 [177]. In literature these cells are called "ex-Th17" cells or "Th1-like"
cells. Studies, as the one from Harbour et al., have reported that the transition from Th17
to Th1-like cells was absolutely required for disease development [264].
Analysis of T-bet in IL-17+IFN-𝛾−, IL-17+IFN-𝛾+ and IL-17−IFN-𝛾+ effector T cells in
C57BL/6 DC-LMP1/CD40 animals showed increased levels of T-bet, where IL17 single posi-
tive cells had the lowest expression and IFN-𝛾 single positive had the highest T-bet expression
(Fig.5.14 A). The latter indicated that IFN-𝛾+ T cells, which are present in high frequen-
cies in transgenic animals on C57BL/6 genetic background, might have actually been the
ex-Th17 cells, which have lost IL-17 expression to become pathogenic Th17 cells. In order
to analyze this possibility, it would be necessary to breed IL-17 and IFN-𝛾+ reporter genes
into the DC-LMP1/CD40 background to follow the fate of Th17 cells and prove the origin
of IFN-𝛾+ T cells in C57BL/6 DC-LMP1/CD40 animals. Hirota et al. have published that
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IL-1R1 expression on IFN-𝛾+ T cells proves their Th17 origin, since real Th1 T cells do
not express this receptor [177]. Unfortunately, a good antibody against IL-1R1 does not yet
exist. Therefore, the only option would be a qPCR for IL-1R1 gene made with cDNA iso-
lated from sorted IL-17−IFN-𝛾+ T cells. Since IL-17 and IFN-𝛾 stainings are intracellular,
this requires cell fixation and makes them unsuitable for cell sort and further qPCR analy-
sis. The cross of two reporter genes into our mouse model would be a long process which
exceeds the time frame of our study. Therefore, we could not prove that IL-17−IFN-𝛾+ T
cells, which were increased in C57BL/6 animals, were ex-Th17 cells and not real Th1 cells.
However, even if we could not claim this for sure our results strongly suggested that F1 DC-
LMP1/CD40 animals had more regulated non pathogenic Th17 cells, while IL-17−IFN-𝛾+ T
cells in C57BL/6 DC-LMP1/CD40 animals had more alternative phenotype and a potential
to develop in pathogenic ex-Th17 cells, which might be responsible for colitis development.
6.2 CD40 signaling induced migration of intestinal DCs
from LP to mLNs
As mentioned in the introduction, the effects of CD40 signaling in DCs in vivo can be studied
in two ways. Additionally to the DC-LMP1/CD40 mouse model, where we have a DC specific
triggering of the CD40 pathway, anti-CD40 mAb can be injected intraperitoneally into a
mouse and its effects on DCs are analyzed later. Both methods have their advantages and
disadvantages. The disadvantage of an anti-CD40 mAb injection and the main reason why we
started our study with DC-LMP1/CD40 animals, is that the effect is systemic. All cells which
express the CD40 molecule are affected, therefore it is impossible to differentiate between
effects of anti-CD40 mAb on DCs and on other cells. Besides DCs CD40 is expressed on
follicular DCs, monocytes, epithelial cells, endothelial cells, hematopoietic progenitor cells and
carcinomas [118, 119, 120, 121]. A study by Kimura et al. has reported the necroinflammatory
response in the liver, as a response to CD40 stimulation of B cells [143]. Therefore the observed
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effect on DCs after the anti-CD40 treatment, could be just a secondary effect of a cytokine
storm induced by some other cell type.
However, the use of anti-CD40 mAb also has some advantages. The biggest limitation
of the DC-LMP1/CD40 mouse model is that the signal can not be induced. This makes
it impossible to identify the first event in the cascade of events. Therefore, we used the
advantage of anti-CD40 injection to demonstrate that CD40 signaling induces the migration
of intestinal DCs from LP to mLNs. After an intraperitoneal injection of anti-CD40 mAb in
wt C57BL/6 animals, CD103+ DC subsets were strongly reduced in LP, while their amount
increased in mLNs [208]. A similar effect of anti-CD40 antibody has previously been published
by the group of Fiona Powrie, who has shown that Rag−/− mice injected with the anti-CD40
antibody had fewer CD103+MHCII+ cells in the spleen [142].
Kinetics experiments performed by Christian Barthels have shown that the amount of the
CD103+ DCs in the mLNs reached its peak 24 h post injection [208]. This finding could be
reproduced and in addition CCR7 protein expression on DCs was analyzed. The expression
of chemokine receptor CCR7 was increased on LP DCs, where CD103+ DCs had the strongest
expression (Fig.5.15).
Since CCR7 is critically important for the migration of LP DCs via afferent lymph to the
T cell areas in mLNs [55, 265], this supports our hypothesis that DCs in LP are reduced due
to their migration. In addition Christian Barthels could demonstrate that DC migration is
induced by direct triggering of DCs by anti-CD40 antibody and not due to some secondary
potentially inflammatory effects. To this end he used mice which lack CD40 specifically
on DCs (CD11c-Cre x CD40𝑓𝑙/𝑓𝑙, (Lutgens et al. unpublished)), where anti-CD40 antibody
treatment could not induce DC migration from the LP to the mLNs [208].
In this study the antibody approach was used to compare the effects of anti-CD40 mAb
treatment on wt BALB/c and C57BL/6 animals. A purpose of this experiment was to in-
vestigate if both mouse strains would react differentially to CD40 triggering. The anti-CD40
antibody treatment of BALB/c and C57BL/6 animals strongly reduced the frequency of
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CD103+CD11b− and CD103+CD11b+ DCs in the LP of both strains (Fig.5.15 A). In ad-
dition, highly increased frequencies of CD103+CD11b− and CD103+CD11b+ DCs in mLNs
could be observed (Fig.5.16 B).
However, it could be seen that even if CD103+CD11b− DCs in anti-CD40 treated BALB/c
animals were strongly reduced, they were still as many as in un-injected C57BL/6 animals.
Since mice of the BALB/c strain had more CD103+CD11b− DCs as compared to C57BL/6
mice, it was possible that the amount of anti-CD40 antibody used for injection was limiting.
However as 200 𝜇g of anti-CD40 antibody were injected, this high amount is hard to imagine
to be insufficient to stimulate all DCs in BALB/c mice.
Analysis of CCR7 on LP DCs from anti-CD40 treated C57BL/6 and BALB/c animals
has shown that stimulation of CD40 pathway in C57BL/6 animals resulted in stronger up-
regulation of CCR7 especially on CD103+ DCs (Fig.5.16 C). The differential up-regulation of
CCR7 chemokine receptor on CD103 positive DCs between C57BL/6 and BALB/c animals,
as a result of CD40 signaling, could explain why constant CD40 triggering in DC-LMP1/CD40
animals had the strongest effect on C57BL/6 transgenic animals, intermediate on F1 and the
smallest ob BALB/c transgenic animals.
Es expected, the analysis of F1 wt animals revealed that they had fewer CD103+CD11b−
DCs than BALB/c, but more than C57BL/6 animals (Fig.5.17 B). However, different steady
state amount of CD103+CD11b− DCs between wt animals of C57BL/6, F1 and BALB/c
strains probably does not explain the differences which were observed between different strains
of DC-LMP1/CD40 animals. While in the anti-CD40 mAb approach it was theoretically pos-
sible to inject an insufficient amount of the antibody as a limiting factor, in the LMP1/CD40
transgene setting every single DC should has received identical CD40 stimulation.
Additionally, the activation status of C57BL/6 and BALB/c DC after in vivo stimulation
with anti-CD40 mAb was compared. We could not observe an effect on expression of MHC
II molecule on DC subsets, while CD80 and CD86 co-stimulatory molecules were strongly
up-regulated (Fig.5.18). From these results, it could be seen that anti-CD40 mAb (Fig.5.18)
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activated DCs more than the LMP1/CD40 transgene (Fig.5.6). A comparison between two
mouse strains has shown that BALB/c DCs responded to anti-CD40 mAb stimulation with a
higher expression of CD80 and CD86 co-stimulatory molecules (Fig.5.19). Higher expression
of co-stimmulatory molecules is a known characteristic of phenotypically mature DCs, which
are known to be more prone in inducing immunity than tolerance [12]. This observation was
therefore in conflict with data from DC-LMP1/CD40 animals, which showed the highest fre-
quencies of iTregs and the lowest frequencies of Th1/Th17 effector cells in transgenic BALB/c
animals. However, in DC-LMP1/CD40 mouse model in contrast to anti-CD40 antibody ap-
proach we could not see that DCs of F1 transgenic animals would be phenotypically more
mature than those from C57BL/6 transgenic animals (Fig.5.7) (BALB/c DC-LMP1/CD40
animals were due to limitation in experimental animals not analyzed).
6.3 Activated CD4 T cells trigger reduction of CD103+
DCs
Our data from in vivo experiments with anti-CD40 mAb and analysis of DC-LMP1/CD40
mice suggested, that CD40 ligand expressing cells in the state of inflammation might be able
to temporarily shut down the tolerogenic mechanisms in order to improve the efficiency of
the immune response. For example, activated CD4+ T cells, which are known to express
CD40 ligand [223], could theoretically triggered the CD40 pathway in DCs and according to
our data caused a reduction of tolerogenic CD103+ DCs. This mechanism could reduce the
capacity to induce tolerance by iTreg induction and would strengthen the immune responses.
We tried to prove our hypothesis with the CD4+CD62L+ transfer model of colitis [198],
which resembles the well known CD45RBℎ𝑖 model [199]. CD4+CD62L+ T cells from donor
wt C57BL/6 mice were transferred to a Rag1−/− recipient, which resulted in chronic colitis.
When Treg depleted T cells are transferred into "empty" Rag1−/− recipient the transferred
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cells strongly proliferate to fill up the empty niche. This activated CD4+ T cells will express
CD40 ligand [223] and their effect on DCs of recipient mice was analyzed in our experiments.
We could shown that 15 days after the adoptive transfer CD103+CD11b− DCs were signif-
icantly reduced in the LP (Fig.5.20). This result supported our hypothesis on CD40-CD40
ligand contribution to the balance between tolerance and immunity as tolerogenic DCs were
significantly reduced.
6.4 SNP genotyping of F2 DC-LMP1/CD40 mouse
strain
An SNP genotyping study using the Ilumina Mouse LD Linkage platform was designed with
the purpose of identifying new candidate genes for different colitis susceptibility between
C57BL/6 and BALB/c transgenic mice strains. We analyzed only F2 DC-LMP1/CD40 with
visible signs of colitis. Since F2 transgenic animals were genetically and phenotypically di-
verse, we were searching for a region in the mouse genome which would have the C57BL/6
genetic origin in all sick F2 DC-LMP1/CD40 animals. Ilumina Mouse LD Linkage platform
included SNP loci spread all over the mouse genome for which the BALB/c and the C57BL/6
mouse strains had different alleles. Since only DC-LMP1/CD40 animals on a C57BL/6 ge-
netic background developed colitis, our hypothesis was that such a region may include a gene
which would be responsible for increased colitis susceptibility in transgenic C57BL/6.
However, we could not identify a region in F2 DC-LMP1/CD40 animals which was ho-
mozygous for the C57BL/6 background. In contrast we found one SNP which was in every
animal heterozygous for C57BL/6 and BALB/c alleles. Although, this was not the outcome
we expected, we analyzed this region of chromosome two further and found 16 candidate
genes which could be relevant for immunological process (Fig.5.21 C). In order to preform a
study with higher resolution we would probably have to include more animals and use an-
other SNP analysis method. In addition it could be important to increase the parameters of
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colitis analysis in our mice, as we most likely have included animals with different degrees
of disease. This would explain why some of the analyzed F2 DC-LMP1/CD40 mice carried
one C57BL/6 and one BALB/c allele for the SNPs in the identified region. Most likely it
would have been important to perform precise pathological analysis with histology for every
animal included in the SNP study. Nevertheless, among the 16 identified candidate genes we
also found IL-1𝛼 and IL-1𝛽 genes, which are profoundly up-regulated in the inflamed colonic
musosa from ulcerative colitis patients [224, 225]. As these genes were of relevance for our
colitis model we continued to study their roles.
6.4.1 Testing IL-1𝛼 and IL-1𝛽 as candidate genes for colitis
susceptibility
Interleukins are a sub-type of cytokines, messenger molecules with strong immunomodulatory
functions. They can be pro- or anti-inflammatory and have been shown to be important for
the differentiation and activation of immune cells [266]. The interleukin one family is known
to be composed of strong pyrogens and T cell co-stimulators and contains in addition to IL-1𝛼
and IL-1𝛽 9 other members [267]. The regulation of these important inflammatory cytokines
especially IL-1𝛽 is very strict, as they can cause several autoinflammatory diseases, chronic
inflammation, septic shock or even death [267].
Since the SNP study performed with F2 DC-LMP1/CD40 animals suggested IL-1𝛼 and
IL-1𝛽 as potential candidate genes for increased colitis susceptibility of DC-LMP1/CD40 on
C67BL/6 genetic background (Fig.5.21 C) and since high levels of these cytokines, which
have a high inflammatory potential have been found in ulcerative colitis patients [224, 225],
we designed several experiments to study their role in our colitis model.
With the first experiment, where we measured IL-1𝛼 and IL-1𝛽 production in LPS primed
BMDCs of C57BL/6 and BALB/c origin, we wanted to analyze if BMDCs of different strains
differ in IL-1𝛼 and IL-1𝛽 transcription caused by triggering of PRRs with LPS. For induction
of IL-1𝛽 cytokine transcription, Toll-like receptors have to be activated with LPS or CpG
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[268]. The IL-1𝛽 precursor is not yet biologically active [269] and can not be secreted. To
become mature, the IL-1𝛽 precursor has to be cleaved by active caspase-1. However, for the
activation of procaspase-1 the activation of the inflammasome is needed. Inflammasomes are
multimeric signalling protein complexes, which detect pathogenic microorganisms or sterile
stressors and upon activation proteolytically cleave procaspase-1 into active caspase-1 [270].
Due to such a tight regulation less than 20 % of the total synthesized IL-1𝛽 precursors leave
the cell in the active 17 kDa form [267].
In contrast, IL-1𝛼 is constitutively expressed and does not need to be activated to be
biologically active [271]. Also, its localization differs from the localization of IL-1𝛽, since it
is mostly found on the cell surface as a membrane-bound IL-1𝛼 [272].
We measured a pro-IL-1𝛽 from the lysed BMDCs and found that C57BL/6 derived BMDCs
produced higher amounts of pro-IL-1𝛽 and IL-1𝛼 as compared to BALB/c derived BMDCs
(Fig.5.22 A).
Because of these in vitro results we tested IL-1 levels in vivo in C57BL/6 and F1 DC-
LMP1/CD40 animals. Interestingly, only C57BL/6 DC-LMP1/CD40 animals had high colo-
nic levels of pro-IL-1𝛽 and IL-1𝛼 cytokines, while F1 transgenic animals and control animals
did not have a detectable amounts (Fig.5.22 B). Unfortunately, without analyzing the colonic
levels of ABX treated C57BL/6 DC-LMP1/CD40 animals it was impossible to know if high
levels of IL-1 cytokines were a cause of the difference which induced the disease in C57BL/6
transgenic mice, or were the consequence of the disease and were induced by some other
unknown mechanism.
However, the fact that IL-1𝛽 is highly inflammatory, precisely regulated [267], found in
patients with ulcerative colitis [224, 225], strongly produced by C57BL/6 BMDCs and at
high levels present in colons of inflamed C57BL/6 DC-LMP1/CD40 animals, made it an
interesting candidate gene for different colitis susceptibility between BALB/c and C57BL/6
mouse strains. However, experiments which revealed that C57BL/6 allele for IL-1𝛽 did not
result in a higher level of IL-1𝛽 and that the sick F2 DC-LMP1/CD40 animals did not have
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the C57BL/6 allele for IL-1𝛽 (Fig.5.23 B and C) were disappointing but did not yet disprove
the hypothesis that high levels of IL-1𝛽 caused colitis in C57BL/6 transgenic animals. Since
IL-1𝛽 is regulated on so many levels, it would be possible that BALB/c and C57BL/6 mice
strains differ in one of the genes important for its regulation. Therefore, we designed some
additional experiments, which will be discussed further on, in order to test the role of IL-1𝛽
in our experimental model of colitis.
6.5 Blocking IL-1𝛽 prevented colitis development in
C57BL/6 transgenic mice
Very high levels of IL-1𝛽 were measured in humans suffering from IBD [273] and it is known
that IL-1𝛽 serves to amplify the mucosal inflammation [274, 275]. Animal studies with the
Helicobacter hepaticus colitis model and T cell transfer model of colitis have identified multiple
mechanisms for how IL-1𝛽 promotes intestinal pathology and demonstrated that its blocking
may be a useful therapeutic approach [276].
Since many years rheumatoid arthritis is being treated with a blockade of IL-1 cytokine
activity, particularly IL-1𝛽 [277]. Three IL-1 blockers used in patients are available on the
market: anakinra [278], canakinumab [279] and rilonacept [280]. So far blocking of IL-1
cytokines is not yet routinely used as a treatment for colitis in humans. However, since
IL-1𝛽 levels were elevated only in C57BL/6 DC-LMP1/CD40 animals which also develop
fatal colitis, we tried to rescue them with anti IL-1𝛽 therapy. For this purpose anti-IL-1𝛽
mAb was used. Anti-IL-1𝛽 mAb was injected intraperitoneally like published previously in
an arthritis model [281]. The dose and the duration of treatment had to be optimized for
DC-LMP1/CD40 colitis model (Fig.5.24 A).
It could be shown that anti-IL-1𝛽 treatment prevented colitis development in C57BL/6 DC-
LMP1/CD40 animals, since their colons were visibly less inflamed than the colons of isotype
control treated animals (Fig.5.24 B). Mice were noticeably heavier (Fig.5.24 C) and lipocalin-
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2, a marker for intestinal inflammation, could not be detected (Fig.5.24 D). This experiment
confirmed that IL-1𝛽 plays a crucial role in the development of colitis in our C57BL/6 DC-
LMP1/CD40 mouse model. However, neutralization of IL-1𝛽 with anakinra has been pre-
viously used in treatment of two patients with severe infant-onset medical-refractory colitis
and fistulizing disease caused by IL-10 receptor deficiency [282]. This treatment successfully
reduced intestinal inflammation and led to clinical, endoscopic and histological improvement
in both patients.
Study by the group of Shouval [282] in IL-10 receptor deficient patients and our experiments
with anti-IL-1𝛽 therapy in C57BL/6 DC-LMP1/CD40 animals therefore suggest that similar
studies should be performed on other colitis models with a purpose to study potential benefits
of IL-1𝛽 blockade in treatment strategies of humans with IBD.
6.6 Blocking IL-1𝛽 prevented the expansion of IFN-𝛾+ T
cells
The observation that blocking of IL-1𝛽 prevented colitis development in C57BL/6 trans-
genic animals made us further investigate the potential mechanism behind this effect. One
possible explanation connecting IL-1𝛽 to the observed differences in C57BL/6 and F1 DC-
LMP1/CD40 mice was that IL-1𝛽 is necessary for the formation of the IL-17−IFN-𝛾+ effector
cells, which were elevated only in C57BL/6 DC-LMP1/CD40 animals (Fig.5.11). If the hy-
pothesis that IL-17+ cells in C57BL/6 DC-LMP1/CD40 animals differentiated to IL-17+IFN-
𝛾+ and IL-17−IFN-𝛾+ T cells would hold true, then these were the so called "ex-Th17" or
"Th1-like" T cells, which were previously shown to be critical for colitis development [264].
These Th1/Th17 cells have also been measured in high frequency in the intestinal mucosa
of IBD patients [283], which further suggests their pathogenicity. The role of IL-1𝛽 in this
hypothesis would be the induction of IFN-𝛾 in Th17 cells, which has previously been reported
by a study in humans with autoimmune disorders [284]. The described mechanism of action
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is that IL-1𝛽 together with TCR stimulation renders Th17 cells responsive for IL-12 cytokine
and stabilizes the T-bet expression which results in pathogenic Th17 cells that express IFN-𝛾
[284]. Given that IL-1𝛽 deficient mice do not develop EAE [285], a multiple sclerosis model
which was also shown to be dependent on IFN-𝛾 expressing Th17 cells [286], further supports
our hypothesis for the role of IL-1𝛽 in DC-LMP1/CD40 model of experimental colitis.
Therefore, it was a logical step to analyze the effector T cell compartment in anti-IL-1𝛽
treated C57BL/6 DC-LMP1/CD40 animals. Like we predicted from literature about Th17
plasticity and differentiation, we could show that blocking IL-1𝛽 blocks the development of
IL-17−IFN-𝛾+ T cells in treated C57BL/6 DC-LMP1/CD40 animals (Fig.5.25).
6.7 LMP1/CD40 transgene induces IL-12-p35
production in CD64+ macrophages
After it was demonstrated that sick C57BL/6 DC-LMP1/CD40 animals had high levels of
intestinal IL-1𝛽 and that anti-IL-1𝛽 therapy could prevent the disease development in these
animals, we wanted to identify which cell subsets produced IL-1𝛽. According to literature,
IL-1 cytokines are primarily produced by stimulated monocytes or macrophages [287]. Con-
firming this, studies with human IBD patients reported that IL-1𝛽 was produced by colonic
lamina propria monocytes [288, 289]. Since our transgenic animals were bread with CD11c
CRE animals which resulted in only CD11c expressing cells receiving constant CD40 stim-
ulation, all these cell subsets were analyzed for the production of IL-1𝛽. No significant up-
regulation of IL-1𝛽 production in CD103+ or CD103− DCs from C57BL/6 DC-LMP1/CD40
animals, when compared to control littermates, could be found (Fig.5.26 A). However, a high
production of IL-1𝛽 in CD64+ LP macrophages, which are also known to express CD11c [50],
could be detected in C57BL/6 DC-LMP1/CD40 animals (Fig.5.26 B). In contrast no elevated
levels of IL-1𝛽 in macrophages from F1 and BALB/c transgenic animals could be measured.
Although, C57BL/6 DC-LMP1/CD40 transgenic animals had substantially higher level of
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IL-1𝛽 cytokine, this was reduced back to background level upon removal of commensal bac-
teria. The latter together with normal levels in F1 and BALB/c transgenic animals showed,
that IL-1𝛽 elevation was a secondary effect of inflammation and was not directly caused by
LMP1/CD40 transgene.
Additionally, we could show that C57BL/6 DC-LMP1/CD40 CD64+ LP macrophages pro-
duced high levels of IL-12-p35 and IL-23-p19 cytokines (Fig.5.26 B). IL-12 and IL-23 cytokines
are heterodimers which share a common p40 subunit, while p35 subunit is IL-12 specific and
p19 is IL-23 specific [290]. However, the analysis of transgenic animals with partial or complete
BALB/c genetic background revealed that IL-23-p19 was reduced in CD64+ LP macrophages
from F1 DC-LMP1/CD40 animals, while its levels in BALB/c transgenic animals resembled
the levels of BALB/c wt controls (Fig.5.26 B). Interestingly, depletion of commensal bacteria
and prevention of inflammation with ABX therapy in C57BL/6 transgenic animals reduced
IL-23-p19 cytokine level back to C57BL/6 background control level (Fig.5.26 B). The latter
suggested that IL-23-p19 was elevated as a consequence of inflammation, which was strong
in C57BL/6 transgenic animals and less intense but detectable in F1 transgenic animals
(Fig.5.1). In contrast IL-12-p35 was found to be elevated in CD64+ macrophages of all trans-
genic animals, even in absence of inflammation (Fig.5.26 B). The latter suggested that this
was the only cytokine elevated due to direct effect of LMP1/CD40 transgene. However, also
IL-12-p35 was the most elevated in C57BL/6 transgenic animals which were not treated with
ABX, what suggest that the presence of inflammation even increased IL-12 production. It
would be interesting to repeat qPCR analysis for IL-12-p35 gene in the way that the IL-12-p35
levels could be directly compared between transgenic animals of different genetic origins. For
this purpose all samples would have to be analyzed in the same qPCR experiment. However,
due to small amounts of cDNA which could be obtained out of low numbers of LP CD64+
macrophages, we did not have enough material for this experiment. Therefore, for this pur-
pose an additional sort of CD64+ macrophages for all DC-LMP1/CD40 strains would be
needed. However, it is known from the literature that BALB/c and C57BL/6 mouse strains
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differ in Th1/Th2 induction capacity [233], since it was shown that C57BL/6 macrophages
upon activation produce more IL-12 than BALB/c mice, which have in contrast more Th2
directed immune response [234, 235].
Taken together our results suggested that LMP1/CD40 transgene caused elevated levels
of IL-12 cytokine in CD64+ macrophages of DC-LMP1/CD40 animals. As it is known from
literature, macrophages from C57BL/6 mouse strain are even in wt animals more prone
to produce high levels of IL-12 than those from BALB/c animals. The latter leads to a
more Th1 directed immune response in C57BL/6 animals [234, 235] and to a certain degree
explains high frequencies of IL-17−IFN-𝛾+ T cells present only in C57BL/6 DC-LMP1/CD40
animals (Fig.5.11). However, while IL-12 has been connected with Th1 cell differentiation,
IL-23 is supposed to play a role in Th17 cells, where it was shown to be important for the
stabilization of genes controlling proinflammatory effector molecules and Th17 cell activation
[290]. Since Th17 cells may also express IFN𝛾 and in some inflammatory settings even stop
with IL-17 expression [177], without IL-17 and IFN𝛾 reporter genes we could not know if
IL-17−IFN-𝛾+ T cells present in C57BL/6 DC-LMP1/CD40 animals were ex-Th17/Th1-like
cells or were the real Th1 cells. Even if we showed that high levels of IL-1𝛽 and IL-23-p19
in C57BL/6 DC-LMP1/CD40 animals were a secondary effect of the inflammation, they still
formed a perfect cytokine milieu for the development of the pathogenic Th17 cells [176, 163].
According to literature IL-1𝛽 renders Th17 cells responsive for IL-12 and thereby stabilizes
T-bet expression in Th17 cells [284]. Our data therefore suggests that C57BL/6 transgenic
animals developed strong inflammation caused by IL-17−IFN-𝛾+ T cells which were caused
by LMP1/CD40 transgene which elevated the IL-12 cytokine levels and were in the next step
even more increased by differentiation from IL-17+ T cells in the perfect cytokine milieu of
the inflammatory settings with the elevated levels of IL-1𝛽 and IL-23-p19.
The expansion of pathogenic Th1/Th17 T cell subsets in C57BL/6 DC-LMP1/CD40 ani-
mals could in addition not be regulated since these animals lacked iTreg cells, which were not
induced due to the absence of tolerogenic CD103+ DC subsets. We could indirectly show that
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CD40 signaling affected BALB/c DCs to a smaller extent than C57BL/6 DCs, since stronger
up-regulation of CCR7 chemokine on C67BL/6 derived CD103+ DCs, as a consequence of
anti-CD40 mAb injection, could be demonstrated. This finding offered the explanation that
due to divergent up-regulation of CCR7 chemokine more CD103+ DCs left LP in C57BL/6
transgenic animals than in BALB/c transgenic animals, while F1 transgenic animals had an
intermediate phenotype. Higher frequencies of CD103+ DCs in BALB/c transgenic animals
caused higher frequencies of iTregs cells, where F1 transgenic animals had intermediate and
C57BL/6 transgenic animals the lowest frequencies.
At the end it seems that all pieces fit together and to a certain degree explain why only
C57BL/6 DC-LMP1/CD40 animals developed colitis. However, some additional experiments
will be needed in order to get a more precise picture picture.
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